data evaluation reports national program of cancer ... the national program of cancer registries...
TRANSCRIPT
Department of Health and Human ServicesCenters for Disease Control and Prevention
Safer . Healthier . People
Data Evaluation ReportsNational Program of Cancer Registries
Cancer Surveillance SystemData Submitted 2017 November
Diagnosis Years 2011-2016
Texas
Data Evaluation Reports - Texas
Introduction........................................................................................................................................................................... Introduction: 1-2
2017 November - Standard Status Report ( SSR1 ) National Data Quality ................................................................. SSR1: 1
SSR1: 2 Report on Quality, Completeness and Timeliness...............................................................................................
SSR1: 3 2017 November CSS Submission Average with Range.............................................................................
2017 November - Submission Summary Report ( SSR2 ) National Data Quality.......................................................... SSR2: 1
Table 1: Submission Summary............................................................................................................................ SSR2: 2
SSR2: 3 Table 2a: Number and Percentage Single and Inter-field Errors.........................................................................
Table 3: Percentage of Over-Ride Flagged Fields -- Grouped by Edit Name and Diagnosis Year...................... SSR2: 5
SSR2: 6 Table 4: Median Percentage of Over-Ride Flags for All 2017 NPCR Data Submissions......................................
DQI: 12017 November - Data Quality Indicator Report ( DQI )...............................................................................................
Table 1: Cancer Survillance Data........................................................................................................................ DQI: 2-5
Estimated Completeness - 2016 ......................................................................................................................... SSR1: 4-6
SSR1: 7-9 Estimated Completeness - 2015 .........................................................................................................................
SSR1: 10-12 Estimated Completeness - 2014 .........................................................................................................................
SSR1: 13-15 Estimated Completeness - 2013 .........................................................................................................................
SSR1: 16-18 Estimated Completeness - 2012 .........................................................................................................................
SSR1: 19-21 Estimated Completeness - 2011 .........................................................................................................................
Table of Contents
SSR2: 4 Table 2b: Inter-Record Edit Errors by Error Type Among Individuals with Multiple Primaries.............................
Department of Health and Human ServicesCenters for Disease Control and Prevention
Safer . Healthier . People
Introduction
The National Program of Cancer Registries (NPCR) provides funds to state and territorial health departments to improve or enhance existing cancer registries; plan for and implement registries where they did not exist; develop model legislation and regulations for states and territories to enhance the viability of registry operations; set standards for data completeness, timeliness, and quality; provide training for registry personnel; and help establish a computerized reporting and data-processing system.
NPCR’s goals are to rapidly establish and standardize the reporting of cancer within and among the states in order to build state and national capacity to do the following: monitor the cancer burden; identify cancer incidence variation for racial and ethnic populations and for regions within a state, between states, and between regions; provide data for research; provide guidance for health resource allocation; respond to public concern and inquiries about cancer; improve planning for future health care needs; and evaluate cancer prevention and control activities.
In 2000, CDC established the NPCR-Cancer Surveillance System (NPCR-CSS) to receive, evaluate, and disseminate data from registries participating in NPCR. The NPCR-CSS is designed to provide cancer incidence data to meet CDC’s public health surveillance responsibilities and to help monitor progress toward NPCR goals. Beginning January 2001, registries annually report their incidence data to CDC from their NPCR reference year forward. The “NPCR reference year” is the first diagnosis year for which a state or territorial cancer registry collected data with the assistance of NPCR funds.
Following each data submission, registries receive a NPCR- CSS Data Evaluation Report detailing the completeness, accuracy and timeliness of their data submission, as demonstrated by meeting the following 5 data quality criteria for each diagnosis year for all cancer sites combined:
Percent Completeness Adjusted for Duplicates: The percentage of observed to expected, unduplicated cases where the expected cases are estimated by using methods developed by the North American Association of Central Cancer Registries (NAACCR) (http://www.naaccr.org/). DER 2017 November case completeness evaluation is based on NAACCR method version 2.2.b.
Unresolved Duplicate Rate: Because some cancer patients receive diagnostic or treatment services at more than one reporting facility, cancer registries perform a procedure to identify and resolve duplicate case reporting to ensure that each cancer case is counted only once. Prior to the submission of data to NPCR-CSS, each registry performs a protocol developed by NAACCR for assessing duplicate cases. This information is reported to CDC at the time of the data submission.
Percent Death Certificate Only Cases: Another measure of the completeness of case ascertainment is the proportion of cases ascertained solely on the basis of a death certificate, with no other information on the case available after the registry has completed a routine procedure known as “death clearance and follow back”.
NPCR-CSS Data Evaluation Report 2017 November (DER 2017 November)
Introduction: 1 of 2
Percent Missing Critical Data Elements (Age, Sex, Race and County): The proportion of cases missing information deemed critical for the reporting of population-based cancer incidence data.
Percent Passing Edits: Edits test the validity and logic of data components. Edits are applied to single field variables, inter-field variables and to multiple records (each record denotes a case of cancer in a patient) in those instances when a patient has multiple cancer diagnoses. Inter-record (IR) edits are run on the entire data submission from the reference year through the most current 22-month data.
How the Data Evaluation Reports are used: The Data Evaluation Reports are used to identify cancer registries whose incidence data meet data standards established by NPCR. The Advanced National Data Quality and the National Data Quality standards are applied to data of the diagnosis years being evaluated. For example, in this report, the Advanced National Data Quality standard will be applied to diagnosis year 2016. The National Data Quality standards will be applied to diagnosis years 2015 and earlier. The USCS publication criteria is a subset of the National Data Quality standard. These criteria are used to identify data for inclusion in the United States Cancer Statistics report(http://apps.nccd.cdc.gov/uscs/) published jointly with the National Cancer Institute's Surveillance Epidemiology and End Results (SEER)Program and in collaboration with NAACCR. In establishing this standard and criteria, CDC recognizes that it may take up to two years before a registry’s incidence data are complete (i.e., all the information on a cancer patient has been reported to and processed by the cancer registry).
When reviewing the Report on Quality, Completeness and Timeliness of Data table, the criteria for each standard (Advanced National Data Quality and National Data Quality) and the USCS publication criteria are highlighted by a color. When all relevant data quality criteria are met, the row corresponding to the diagnosis year will be highlighted. CDC expects that all registries should achieve these NPCR program standards and in so doing be included in the USCS report.
NPCR-CSS Data Evaluation Report 2017 November (DER 2017 November)
Introduction: 2 of 2
Standard Status Report (SSR1)National Program of Cancer Registries
Cancer Surveillance System Data Submitted 2017 November
Diagnosis Years 2011-2016
Texas
Department of Health and Human ServicesCenters for Disease Control and Prevention
Safer . Healthier . People
SSR1: 1 of 21
National Program of Cancer Registries - Cancer Surveillance System
SSR1 - Standard Status Report - 2017 November
Texas
NPCR Standards Grouping
Diagnosis Year**
Percent Completeness Adjusted for Duplicates*
Unresolved Duplicate Rates
(per 1,000)
Percent Death Certificate
Only
Percent Missing or Unknown Data Elements
Percent Passing Single and Inter-
field Edits
1995 -2015 Percent Passing
Inter-record Edits***Age Sex Race County
Advanced National Data Quality 2016 76.15 0.00 6.48 0.00 0.01 0.95 0.02 100.00 N/A
National Data Quality
2015 96.13 0.00 2.75 0.00 0.00 0.83 0.00 100.00 100.00
2014 96.31 0.00 2.63 0.00 0.00 0.42 0.00 100.00 100.00
2013 94.43 0.00 2.62 0.00 0.00 0.33 0.01 100.00 100.00
2012 94.60 0.00 2.58 0.00 0.00 0.20 0.01 100.00 100.00
2011 93.78 0.00 2.17 0.00 0.00 0.08 0.00 100.00 100.00
NDC: Death Clearance Not DoneN/A: Not Applicable* See the Introduction section of this report for a description of the data quality criteria and evaluation methods.** Only data from the most recent six diagnosis years are presented here. Highlighted rows denote the diagnosis years for which data met program and/or publication standards. Colors correspond to the data standard met. Diagnosis years that did not meet program and/or publication standards are not highlighted. *** Calculated as ( 1 - # of patients with a inter-record edit error/# of patients with more than one record) x 100.**** The measurement error is the error allowances for determining if data elements have met the standard, and may vary following review by CDC.
STANDARD
Advanced National Data Quality Standard 90.00 <=2.00 N/A <=3.00 <=3.00 <=5.00 <=3.00 97.00 N/A
National Data Quality Standard 95.00 <=1 <=3 <=2 <=2 <=3 <=2 99.00 99.00
USCS Publication Standard 90.00 N/A <=5 <=3 <=3 <=5 N/A 97.00 97.00
Measurement Error**** -1.0 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 N/A N/A
Report on Quality, Completeness and Timelines of Data*
SSR1: 2 of 21
Report on Quality, Completeness and Timelines of Data - 2017 November CSS Submission Media with Range
N/A: Not Applicable.* Only 24-month data from the most recent five diagnosis year are presented here.** Calculated as (1 - # of patients with a inter-record edit error/# of patients with more than one record) x 100.*** The measurement error is the error allowance for determining if data elements have met the standard, and may vary following review by CDC.
Percent Missing or Unknown Data Elements
NPCRStandardsGrouping
Diagnosis Year* Statistic
Percent CompletenessAdjusted for Duplicates
UnresolvedDuplicate Rate
(per 1,000)
Percent DeathCertificate Only
CasesAge Sex Race County
Percent Passing Single and Inter-field
Edits
Percent PassingInter-record
Edits**
Advanced National Data
Quality2016 Median
Range84.44
25.33 - 103.910.00
0.00 - 0.000.00
0.00 - 5.500.00
0.00 - 0.000.00
0.00 - 0.090.95
0.00 - 9.100.02
0.00 - 11.04100.00
49.01 - 100.00 N/A
National Data Quality
2015 MedianRange
99.0877.89 - 112.45
0.000.00 - 2.50
1.670.52 - 3.98
0.000.00 - 0.04
0.000.00 - 0.09
0.900.00 - 3.38
0.010.00 - 2.76
100.0098.99 - 100.00
2014 MedianRange
99.6283.36 - 111.28
0.000.00 - 0.87
1.850.41 - 4.33
0.000.00 - 0.02
0.000.00 - 0.03
0.920.00 - 2.59
0.020.00 - 0.88
100.0099.11 - 100.00
2013 MedianRange
98.5184.73 - 112.61
0.000.00 - 0.87
1.530.36 - 4.69
0.000.00 - 0.02
0.000.00 - 0.03
0.890.00 - 3.01
0.010.00 - 0.44
100.0098.41 - 100.00
10099.92 - 100
2012 MedianRange
98.2786.07 - 113.33
0.000.00 - 0.87
1.720.11 - 5.31
0.000.00 - 0.02
0.000.00 - 0.08
0.900.00 - 2.28
0.010.00 - 0.73
100.0098.74 - 100.00
2011 MedianRange
97.7287.96 - 108.90
0.000.00 - 0.87
1.760.07 - 6.16
0.000.00 - 0.03
0.000.00 - 0.07
0.950.00 - 2.25
0.010.00 - 0.77
100.0098.33 - 100.00
STANDARD
Advanced National Data Quality Standard 90.00 <=2.00 N/A <=3.00 <=3.00 <=5.00 <=3.00 97.00 N/A
National Data Quality Standard 95.00 <=1 <=3 <=2 <=2 <=3 <=2 99.00 99.00
USCS Publication Standard 90.00 N/A <=5 <=3 <=3 <=5 N/A 97.00 97.00
Measurement Error*** -0.1 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 N/A N/A
National Program of Cancer Registries - Cancer Surveillance System
SSR1 - Standard Status Report - 2017 November
CSS Submission Median with Range
SSR1: 3 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Blacks
Texas - 2016
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Males 2016 2014 - 2015 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2015 - 2016 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 9.13 5.01 1.82 4.83 2.95 14.78 61.78 5.19 0.93 4.94 14.58 62.65Esophagus 4.52 4.51 1.00 5.82 1.14 5.16 87.62 5.00 1.17 4.66 5.33 84.82Stomach 11.08 7.08 1.56 8.34 1.65 11.69 94.73 7.80 1.07 7.18 11.86 93.45Colon and Rectum 42.18 24.84 1.70 24.52 2.20 54.66 77.16 26.72 0.92 24.43 53.77 78.45Liver 19.90 13.36 1.49 11.52 1.43 19.05 104.45 14.52 0.79 12.81 18.26 108.96Pancreas 13.32 14.70 0.91 14.82 1.14 16.76 79.47 14.40 1.03 14.78 16.86 79.02Lung and Bronchus 58.86 64.81 0.91 65.28 1.27 82.64 71.23 69.09 0.94 64.10 81.72 72.02
Melanoma of the Skin
ProstateUrinary Bladder 12.97 5.38 2.41 5.34 3.66 19.67 65.94 5.08 1.05 5.44 19.87 65.26Kidney and Renal Pelvis 19.52 6.80 2.87 5.54 4.46 30.31 64.38 6.55 0.85 6.59 29.38 66.42Brain and Other Nervous System 3.11 2.92 1.06 3.19 1.50 4.39 70.78 3.09 1.03 2.94 4.42 70.32Hodgkin's Disease 2.42 0.43 5.62 0.39 7.74 3.34 72.63 0.34 1.15 0.44 3.44 70.45Non-Hodgkin's Lymphomas 10.49 4.68 2.24 5.36 3.11 14.55 72.09 4.87 1.10 4.78 14.84 70.68Multiple Myeloma 11.20 7.35 1.52 7.47 2.07 15.23 73.54 7.68 0.97 7.31 15.15 73.93Leukemias 7.67 8.17 0.94 7.40 1.81 14.77 51.93 8.29 0.89 7.99 14.45 53.07
Sum of Rates for Black Males 226.36 307.00 73.73 303.93 74.48
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Females 2016 2014 - 2015 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2015 - 2016 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 3.98 1.08 3.68 1.35 3.73 4.04 98.60 1.17 1.16 1.12 4.16 95.62Esophagus 1.34 1.82 0.74 1.77 1.27 2.31 58.17 1.51 1.17 1.89 2.39 56.24Stomach 6.48 3.29 1.97 3.92 1.91 6.30 102.81 3.79 1.03 3.32 6.35 102.10Colon and Rectum 34.30 16.18 2.12 16.09 2.48 40.17 85.37 16.65 0.97 16.07 39.90 85.95Liver 4.33 4.23 1.02 3.31 1.33 5.62 76.94 3.94 0.84 4.09 5.44 79.48Pancreas 12.39 11.60 1.07 12.17 1.20 13.86 89.34 11.76 1.04 11.68 13.96 88.71Lung and Bronchus 35.04 30.17 1.16 33.60 1.44 43.40 80.73 33.51 1.00 30.19 43.43 80.68
Melanoma of the Skin
BreastCervix 7.80 3.66 2.13 3.70 2.43 8.92 87.52 3.98 0.93 3.61 8.79 88.77Corpus and Uterus,NOS 19.00 7.98 2.38 8.31 3.10 24.72 76.88 7.65 1.09 8.11 25.15 75.57Ovary 8.02 5.35 1.50 6.32 1.44 7.71 104.07 5.63 1.12 5.48 7.89 101.61Urinary Bladder 3.78 2.16 1.75 2.42 2.68 5.79 65.28 2.10 1.15 2.23 5.97 63.38Kidney and Renal Pelvis 9.99 2.85 3.50 2.38 5.37 15.31 65.23 2.96 0.80 2.74 14.71 67.91Brain and Other Nervous System 2.91 2.81 1.04 2.13 1.63 4.58 63.55 2.39 0.89 2.75 4.48 64.93Hodgkin's Disease 2.04 0.45 4.54 0.24 9.50 4.27 47.76 0.34 0.70 0.42 4.02 50.79Non-Hodgkin's Lymphomas 8.61 3.07 2.80 3.38 3.53 10.86 79.27 3.38 1.00 3.07 10.86 79.30Multiple Myeloma 10.46 5.11 2.05 5.46 2.10 10.74 97.40 5.65 0.97 5.07 10.67 98.04Leukemias 6.75 4.71 1.43 4.47 1.96 9.23 73.16 4.51 0.99 4.70 9.20 73.32
Sum of Rates for Black Females 177.22 217.84 81.35 217.38 81.53
Sum of Rates for Blacks 201.05 261.07 77.01 259.34 78.11
SSR1: 4 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Whites
Texas - 2016
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Males 2016 2014 - 2015 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2015 - 2016 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 13.29 4.06 3.27 3.81 4.76 19.33 68.76 4.10 0.93 4.00 19.06 69.73Esophagus 6.29 5.99 1.05 7.59 1.09 6.50 96.70 6.13 1.24 6.28 6.81 92.31Stomach 6.18 4.41 1.40 3.74 2.20 9.70 63.70 4.47 0.84 4.27 9.39 65.85Colon and Rectum 35.05 17.03 2.06 16.83 2.62 44.63 78.55 17.47 0.96 16.90 44.30 79.13Liver 12.57 9.51 1.32 6.98 1.44 13.65 92.09 9.60 0.73 8.99 12.90 97.40Pancreas 12.01 11.65 1.03 12.60 1.14 13.23 90.74 11.59 1.09 11.85 13.46 89.20Lung and Bronchus 45.68 45.35 1.01 54.08 1.31 59.37 76.94 49.10 1.10 46.27 60.58 75.41Melanoma of Skin 11.38 3.57 3.19 4.47 6.87 24.48 46.46 3.75 1.19 3.70 25.42 44.75
ProstateUrinary Bladder 21.49 6.73 3.19 8.02 4.68 31.52 68.20 6.70 1.20 7.00 32.76 65.61Kidney and Renal Pelvis 20.27 6.43 3.15 5.79 3.84 24.69 82.08 6.65 0.87 6.26 24.05 84.26Brain and Other Nervous System 6.27 5.19 1.21 5.78 1.42 7.38 84.85 5.24 1.10 5.29 7.54 83.12Hodgkin's Disease 1.97 0.50 3.94 0.43 7.09 3.54 55.57 0.54 0.81 0.48 3.40 57.80Non-Hodgkin's Lymphomas 15.54 6.96 2.23 7.75 3.02 21.03 73.90 7.39 1.05 7.03 21.23 73.20Multiple Myeloma 6.07 3.43 1.77 4.00 1.86 6.39 94.96 3.73 1.07 3.48 6.49 93.59Leukemias 12.47 8.94 1.40 9.33 1.95 17.46 71.41 9.18 1.02 8.96 17.52 71.19
Sum of Rates for White Males 226.52 302.92 74.78 304.91 74.29
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Females 2016 2014 - 2015 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2015 - 2016 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 4.41 1.38 3.21 1.33 4.93 6.78 65.05 1.39 0.96 1.36 6.73 65.61Esophagus 1.19 1.15 1.04 1.47 1.19 1.37 87.18 1.17 1.26 1.21 1.44 82.94Stomach 3.88 2.47 1.57 2.00 1.99 4.92 78.88 2.49 0.80 2.37 4.73 82.09Colon and Rectum 25.52 10.81 2.36 11.88 2.82 30.51 83.65 11.20 1.06 10.95 30.88 82.64Liver 4.10 3.29 1.25 2.25 1.33 4.39 93.39 3.31 0.68 3.08 4.11 99.80Pancreas 9.73 8.77 1.11 9.37 1.15 10.11 96.27 8.78 1.07 8.89 10.25 94.99Lung and Bronchus 33.43 29.54 1.13 36.76 1.47 43.43 76.97 30.99 1.19 30.64 45.04 74.21Melanoma of Skin 6.30 1.36 4.63 1.88 10.34 14.06 44.78 1.45 1.30 1.44 14.91 42.24
BreastCervix 7.82 2.96 2.64 2.17 3.42 10.12 77.22 2.79 0.78 2.83 9.67 80.83Corpus and Uterus,NOS 20.41 3.76 5.43 4.27 6.21 23.33 87.51 3.66 1.17 3.88 24.11 84.66Ovary 8.22 6.32 1.30 7.45 1.57 9.92 82.85 6.73 1.11 6.45 10.13 81.10Urinary Bladder 4.73 1.73 2.73 2.19 4.20 7.27 65.04 1.77 1.24 1.81 7.61 62.11Kidney and Renal Pelvis 11.12 2.84 3.92 2.47 4.68 13.29 83.69 2.95 0.84 2.74 12.85 86.52Brain and Other Nervous System 5.24 3.84 1.36 3.88 1.55 5.95 88.09 3.69 1.05 3.88 6.01 87.18Hodgkin's Disease 1.60 0.24 6.60 0.26 9.05 2.20 72.88 0.28 0.96 0.24 2.18 73.53Non-Hodgkin's Lymphomas 10.88 4.19 2.59 4.64 3.47 14.56 74.72 4.43 1.05 4.23 14.70 74.02Multiple Myeloma 3.66 2.34 1.56 2.43 1.89 4.44 82.56 2.28 1.06 2.37 4.49 81.51Leukemias 7.62 4.52 1.69 5.17 2.14 9.69 78.64 5.03 1.03 4.55 9.75 78.20
Sum of Rates for White Females 169.87 216.33 78.52 219.59 77.36
Sum of Rates for Whites 198.12 259.51 76.34 262.13 75.83
SSR1: 5 of 21
National Program of Cancer Registries - Cancer Surveillance System
SSR1 - Standard Status Report - 2017 November
Texas - 2016
Estimated Completeness Summary
Interim Completeness Estimates Adjusted for Reference Mortality
Whites Blacks Race Proportional
Percent Complete
Population Percent Complete
Population Percent Complete
Population
75.83 22,447,449 78.11 3,634,085 76.15 26,081,534
Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records
TotalIncedence Cases 86753
AdjustedTotal Incidence Cases 86753
Race Proportional Completeness,Adjusted for Reference Mortality 76.15
ExpectedIncidence Cases 113930
%Unresolved Duplicates* 0.00
Final Completeness Estimates,Adjusted for Reference Mortalityand Duplicate Records 76.15
* 0.00 indicates all duplicates are resolved.
SSR1: 6 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Blacks
Texas - 2015
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Males 2015 2014 - 2015 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2014 - 2015 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 11.06 5.01 2.21 4.83 2.95 14.78 74.82 5.19 0.93 4.94 14.58 75.88Esophagus 5.42 4.51 1.20 5.82 1.14 5.16 105.04 5.00 1.17 4.66 5.33 101.68Stomach 11.14 7.08 1.57 8.34 1.65 11.69 95.29 7.80 1.07 7.18 11.86 94.00Colon and Rectum 56.16 24.84 2.26 24.52 2.20 54.66 102.73 26.72 0.92 24.43 53.77 104.45Liver 19.94 13.36 1.49 11.52 1.43 19.05 104.69 14.52 0.79 12.81 18.26 109.21Pancreas 17.58 14.70 1.20 14.82 1.14 16.76 104.86 14.40 1.03 14.78 16.86 104.25Lung and Bronchus 78.13 64.81 1.21 65.28 1.27 82.64 94.55 69.09 0.94 64.10 81.72 95.61
Melanoma of the Skin
ProstateUrinary Bladder 15.44 5.38 2.87 5.34 3.66 19.67 78.52 5.08 1.05 5.44 19.87 77.71Kidney and Renal Pelvis 26.08 6.80 3.84 5.54 4.46 30.31 86.03 6.55 0.85 6.59 29.38 88.76Brain and Other Nervous System 4.57 2.92 1.57 3.19 1.50 4.39 104.06 3.09 1.03 2.94 4.42 103.38Hodgkin's Disease 3.35 0.43 7.78 0.39 7.74 3.34 100.55 0.34 1.15 0.44 3.44 97.54Non-Hodgkin's Lymphomas 15.14 4.68 3.23 5.36 3.11 14.55 104.09 4.87 1.10 4.78 14.84 102.04Multiple Myeloma 16.07 7.35 2.19 7.47 2.07 15.23 105.51 7.68 0.97 7.31 15.15 106.08Leukemias 15.28 8.17 1.87 7.40 1.81 14.77 103.46 8.29 0.89 7.99 14.45 105.72
Sum of Rates for Black Males 295.37 307.00 96.21 303.93 97.18
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Females 2015 2014 - 2015 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2014 - 2015 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 4.84 1.08 4.47 1.35 3.73 4.04 119.80 1.17 1.16 1.12 4.16 116.18Esophagus 1.98 1.82 1.08 1.77 1.27 2.31 85.54 1.51 1.17 1.89 2.39 82.70Stomach 7.29 3.29 2.21 3.92 1.91 6.30 115.67 3.79 1.03 3.32 6.35 114.87Colon and Rectum 38.67 16.18 2.39 16.09 2.48 40.17 96.26 16.65 0.97 16.07 39.90 96.92Liver 5.86 4.23 1.39 3.31 1.33 5.62 104.22 3.94 0.84 4.09 5.44 107.65Pancreas 14.85 11.60 1.28 12.17 1.20 13.86 107.14 11.76 1.04 11.68 13.96 106.39Lung and Bronchus 43.64 30.17 1.45 33.60 1.44 43.40 100.55 33.51 1.00 30.19 43.43 100.50
Melanoma of the Skin
BreastCervix 9.05 3.66 2.47 3.70 2.43 8.92 101.48 3.98 0.93 3.61 8.79 102.93Corpus and Uterus,NOS 21.69 7.98 2.72 8.31 3.10 24.72 87.75 7.65 1.09 8.11 25.15 86.26Ovary 8.86 5.35 1.65 6.32 1.44 7.71 114.91 5.63 1.12 5.48 7.89 112.20Urinary Bladder 5.43 2.16 2.51 2.42 2.68 5.79 93.74 2.10 1.15 2.23 5.97 91.01Kidney and Renal Pelvis 14.38 2.85 5.04 2.38 5.37 15.31 93.88 2.96 0.80 2.74 14.71 97.73Brain and Other Nervous System 4.46 2.81 1.59 2.13 1.63 4.58 97.41 2.39 0.89 2.75 4.48 99.53Hodgkin's Disease 1.56 0.45 3.48 0.24 9.50 4.27 36.61 0.34 0.70 0.42 4.02 38.94Non-Hodgkin's Lymphomas 11.27 3.07 3.67 3.38 3.53 10.86 103.80 3.38 1.00 3.07 10.86 103.83Multiple Myeloma 11.03 5.11 2.16 5.46 2.10 10.74 102.70 5.65 0.97 5.07 10.67 103.38Leukemias 8.40 4.71 1.78 4.47 1.96 9.23 91.09 4.51 0.99 4.70 9.20 91.29
Sum of Rates for Black Females 213.27 217.84 97.90 217.38 98.11
Sum of Rates for Blacks 253.05 261.05 96.94 259.32 97.66
SSR1: 7 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Whites
Texas - 2015
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Males 2015 2014 - 2015 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2014 - 2015 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 18.28 4.06 4.50 3.81 4.76 19.33 94.54 4.10 0.93 4.00 19.06 95.87Esophagus 7.08 5.99 1.18 7.59 1.09 6.50 108.86 6.13 1.24 6.28 6.81 103.91Stomach 8.08 4.41 1.83 3.74 2.20 9.70 83.30 4.47 0.84 4.27 9.39 86.10Colon and Rectum 44.96 17.03 2.64 16.83 2.62 44.63 100.75 17.47 0.96 16.90 44.30 101.50Liver 15.12 9.51 1.59 6.98 1.44 13.65 110.78 9.60 0.73 8.99 12.90 117.17Pancreas 14.12 11.65 1.21 12.60 1.14 13.23 106.68 11.59 1.09 11.85 13.46 104.87Lung and Bronchus 59.18 45.35 1.30 54.08 1.31 59.37 99.68 49.10 1.10 46.27 60.58 97.69Melanoma of Skin 19.13 3.57 5.37 4.47 6.87 24.48 78.14 3.75 1.19 3.70 25.42 75.27
ProstateUrinary Bladder 26.56 6.73 3.95 8.02 4.68 31.52 84.26 6.70 1.20 7.00 32.76 81.07Kidney and Renal Pelvis 24.63 6.43 3.83 5.79 3.84 24.69 99.74 6.65 0.87 6.26 24.05 102.39Brain and Other Nervous System 7.06 5.19 1.36 5.78 1.42 7.38 95.67 5.24 1.10 5.29 7.54 93.73Hodgkin's Disease 2.47 0.50 4.95 0.43 7.09 3.54 69.86 0.54 0.81 0.48 3.40 72.67Non-Hodgkin's Lymphomas 20.84 6.96 2.99 7.75 3.02 21.03 99.13 7.39 1.05 7.03 21.23 98.19Multiple Myeloma 7.35 3.43 2.14 4.00 1.86 6.39 114.94 3.73 1.07 3.48 6.49 113.27Leukemias 17.25 8.94 1.93 9.33 1.95 17.46 98.79 9.18 1.02 8.96 17.52 98.48
Sum of Rates for White Males 292.11 302.92 96.43 304.91 95.80
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Females 2015 2014 - 2015 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2014 - 2015 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 5.70 1.38 4.14 1.33 4.93 6.78 84.01 1.39 0.96 1.36 6.73 84.74Esophagus 1.50 1.15 1.30 1.47 1.19 1.37 109.44 1.17 1.26 1.21 1.44 104.11Stomach 4.79 2.47 1.94 2.00 1.99 4.92 97.39 2.49 0.80 2.37 4.73 101.36Colon and Rectum 30.43 10.81 2.81 11.88 2.82 30.51 99.76 11.20 1.06 10.95 30.88 98.55Liver 5.20 3.29 1.58 2.25 1.33 4.39 118.45 3.31 0.68 3.08 4.11 126.58Pancreas 10.38 8.77 1.18 9.37 1.15 10.11 102.67 8.78 1.07 8.89 10.25 101.30Lung and Bronchus 41.66 29.54 1.41 36.76 1.47 43.43 95.93 30.99 1.19 30.64 45.04 92.49Melanoma of Skin 10.89 1.36 8.01 1.88 10.34 14.06 77.44 1.45 1.30 1.44 14.91 73.05
BreastCervix 9.38 2.96 3.17 2.17 3.42 10.12 92.65 2.79 0.78 2.83 9.67 96.98Corpus and Uterus,NOS 22.24 3.76 5.92 4.27 6.21 23.33 95.34 3.66 1.17 3.88 24.11 92.23Ovary 10.84 6.32 1.72 7.45 1.57 9.92 109.29 6.73 1.11 6.45 10.13 106.98Urinary Bladder 5.83 1.73 3.37 2.19 4.20 7.27 80.21 1.77 1.24 1.81 7.61 76.59Kidney and Renal Pelvis 13.68 2.84 4.82 2.47 4.68 13.29 102.99 2.95 0.84 2.74 12.85 106.47Brain and Other Nervous System 5.77 3.84 1.50 3.88 1.55 5.95 97.06 3.69 1.05 3.88 6.01 96.06Hodgkin's Disease 2.36 0.24 9.69 0.26 9.05 2.20 107.08 0.28 0.96 0.24 2.18 108.03Non-Hodgkin's Lymphomas 14.04 4.19 3.35 4.64 3.47 14.56 96.46 4.43 1.05 4.23 14.70 95.55Multiple Myeloma 5.25 2.34 2.24 2.43 1.89 4.44 118.28 2.28 1.06 2.37 4.49 116.76Leukemias 10.79 4.52 2.39 5.17 2.14 9.69 111.29 5.03 1.03 4.55 9.75 110.67
Sum of Rates for White Females 210.73 216.33 97.41 219.59 95.97
Sum of Rates for Whites 251.31 259.50 96.84 262.13 95.89
SSR1: 8 of 21
National Program of Cancer Registries - Cancer Surveillance System
SSR1 - Standard Status Report - 2017 November
Texas - 2015
Estimated Completeness Summary
Interim Completeness Estimates Adjusted for Reference Mortality
Whites Blacks Race Proportional
Percent Complete
Population Percent Complete
Population Percent Complete
Population
95.89 22,174,011 97.66 3,548,101 96.13 25,722,112
Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records
TotalIncedence Cases 107298
AdjustedTotal Incidence Cases 107298
Race Proportional Completeness,Adjusted for Reference Mortality 96.13
ExpectedIncidence Cases 111617
%Unresolved Duplicates* 0.00
Final Completeness Estimates,Adjusted for Reference Mortalityand Duplicate Records 96.13
* 0.00 indicates all duplicates are resolved.
SSR1: 9 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Blacks
Texas - 2014
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Males 2014 2013 - 2014 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2013 - 2014 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 14.34 4.99 2.87 4.83 2.95 14.74 97.32 5.19 0.93 4.92 14.53 98.70Esophagus 7.17 4.93 1.45 5.82 1.14 5.64 127.20 5.00 1.17 5.09 5.82 123.13Stomach 12.84 8.54 1.50 8.34 1.65 14.11 90.99 7.80 1.07 8.66 14.30 89.75Colon and Rectum 58.34 26.45 2.21 24.52 2.20 58.22 100.21 26.72 0.92 26.02 57.26 101.89Liver 21.30 14.22 1.50 11.52 1.43 20.27 105.07 14.52 0.79 13.63 19.43 109.60Pancreas 16.29 14.55 1.12 14.82 1.14 16.60 98.14 14.40 1.03 14.64 16.70 97.58Lung and Bronchus 85.43 70.26 1.22 65.28 1.27 89.59 95.36 69.09 0.94 69.49 88.60 96.42
Melanoma of the Skin
ProstateUrinary Bladder 19.19 5.28 3.63 5.34 3.66 19.30 99.40 5.08 1.05 5.33 19.50 98.37Kidney and Renal Pelvis 27.72 6.32 4.39 5.54 4.46 28.17 98.39 6.55 0.85 6.12 27.31 101.51Brain and Other Nervous System 4.60 3.04 1.51 3.19 1.50 4.57 100.55 3.09 1.03 3.06 4.60 99.89Hodgkin's Disease 2.94 0.42 7.05 0.39 7.74 3.23 91.07 0.34 1.15 0.43 3.32 88.34Non-Hodgkin's Lymphomas 18.27 4.73 3.86 5.36 3.11 14.71 124.25 4.87 1.10 4.83 15.00 121.81Multiple Myeloma 15.12 7.30 2.07 7.47 2.07 15.13 99.89 7.68 0.97 7.27 15.05 100.42Leukemias 13.73 7.53 1.82 7.40 1.81 13.61 100.86 8.29 0.89 7.37 13.32 103.07
Sum of Rates for Black Males 317.27 317.89 99.81 314.77 100.80
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Females 2014 2013 - 2014 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2013 - 2014 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 4.25 1.33 3.20 1.35 3.73 4.96 85.69 1.17 1.16 1.37 5.12 83.10Esophagus 2.04 1.37 1.49 1.77 1.27 1.74 117.78 1.51 1.17 1.42 1.80 113.88Stomach 6.38 3.67 1.74 3.92 1.91 7.01 91.01 3.79 1.03 3.69 7.06 90.39Colon and Rectum 38.82 15.43 2.52 16.09 2.48 38.32 101.32 16.65 0.97 15.33 38.06 102.01Liver 5.48 4.03 1.36 3.31 1.33 5.36 102.27 3.94 0.84 3.90 5.19 105.63Pancreas 15.52 11.26 1.38 12.17 1.20 13.46 115.30 11.76 1.04 11.34 13.56 114.49Lung and Bronchus 44.11 32.61 1.35 33.60 1.44 46.91 94.04 33.51 1.00 32.63 46.93 93.99
Melanoma of the Skin
BreastCervix 9.34 3.89 2.40 3.70 2.43 9.46 98.72 3.98 0.93 3.83 9.33 100.13Corpus and Uterus,NOS 22.86 8.27 2.77 8.31 3.10 25.62 89.22 7.65 1.09 8.41 26.07 87.70Ovary 10.15 5.32 1.91 6.32 1.44 7.66 132.51 5.63 1.12 5.45 7.84 129.38Urinary Bladder 5.61 1.83 3.06 2.42 2.68 4.91 114.30 2.10 1.15 1.89 5.05 110.97Kidney and Renal Pelvis 13.41 2.37 5.65 2.38 5.37 12.75 105.13 2.96 0.80 2.28 12.25 109.45Brain and Other Nervous System 4.28 2.45 1.75 2.13 1.63 4.00 107.05 2.39 0.89 2.40 3.91 109.38Hodgkin's Disease 1.76 0.36 4.92 0.24 9.50 3.40 51.74 0.34 0.70 0.34 3.20 55.02Non-Hodgkin's Lymphomas 12.07 3.33 3.62 3.38 3.53 11.77 102.56 3.38 1.00 3.33 11.77 102.59Multiple Myeloma 11.22 5.59 2.01 5.46 2.10 11.75 95.49 5.65 0.97 5.55 11.68 96.12Leukemias 9.86 4.32 2.28 4.47 1.96 8.45 116.67 4.51 0.99 4.31 8.43 116.92
Sum of Rates for Black Females 217.17 217.53 99.84 217.24 99.97
Sum of Rates for Blacks 265.66 266.14 99.82 264.48 100.37
SSR1: 10 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Whites
Texas - 2014
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Males 2014 2013 - 2014 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2013 - 2014 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 17.62 4.30 4.10 3.81 4.76 20.49 86.02 4.10 0.93 4.24 20.20 87.23Esophagus 6.91 5.93 1.17 7.59 1.09 6.43 107.43 6.13 1.24 6.21 6.74 102.55Stomach 9.20 4.67 1.97 3.74 2.20 10.26 89.72 4.47 0.84 4.51 9.92 92.74Colon and Rectum 43.98 17.47 2.52 16.83 2.62 45.80 96.02 17.47 0.96 17.35 45.47 96.73Liver 15.85 9.71 1.63 6.98 1.44 13.94 113.71 9.60 0.73 9.18 13.18 120.27Pancreas 13.47 11.42 1.18 12.60 1.14 12.97 103.83 11.59 1.09 11.62 13.20 102.07Lung and Bronchus 62.44 48.12 1.30 54.08 1.31 63.00 99.11 49.10 1.10 49.09 64.27 97.14Melanoma of Skin 19.97 3.89 5.13 4.47 6.87 26.74 74.69 3.75 1.19 4.04 27.76 71.95
ProstateUrinary Bladder 28.70 6.86 4.18 8.02 4.68 32.11 89.38 6.70 1.20 7.13 33.37 85.99Kidney and Renal Pelvis 24.55 6.51 3.77 5.79 3.84 25.01 98.16 6.65 0.87 6.34 24.36 100.77Brain and Other Nervous System 7.87 5.32 1.48 5.78 1.42 7.57 103.96 5.24 1.10 5.43 7.73 101.85Hodgkin's Disease 2.80 0.49 5.68 0.43 7.09 3.50 80.13 0.54 0.81 0.47 3.36 83.35Non-Hodgkin's Lymphomas 21.87 7.58 2.89 7.75 3.02 22.90 95.53 7.39 1.05 7.65 23.12 94.62Multiple Myeloma 7.89 3.73 2.12 4.00 1.86 6.96 113.47 3.73 1.07 3.79 7.06 111.83Leukemias 18.57 9.09 2.04 9.33 1.95 17.76 104.57 9.18 1.02 9.11 17.81 104.25
Sum of Rates for White Males 301.70 315.42 95.65 317.55 95.01
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Females 2014 2013 - 2014 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2013 - 2014 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 6.20 1.30 4.78 1.33 4.93 6.40 96.92 1.39 0.96 1.29 6.34 97.77Esophagus 1.45 1.16 1.25 1.47 1.19 1.38 105.00 1.17 1.26 1.22 1.45 99.88Stomach 4.65 2.46 1.89 2.00 1.99 4.91 94.66 2.49 0.80 2.37 4.72 98.52Colon and Rectum 30.83 11.07 2.78 11.88 2.82 31.25 98.66 11.20 1.06 11.21 31.63 97.46Liver 5.15 3.23 1.59 2.25 1.33 4.30 119.59 3.31 0.68 3.02 4.03 127.80Pancreas 10.50 8.81 1.19 9.37 1.15 10.16 103.38 8.78 1.07 8.93 10.30 102.00Lung and Bronchus 43.99 30.62 1.44 36.76 1.47 45.01 97.72 30.99 1.19 31.76 46.69 94.21Melanoma of Skin 10.25 1.40 7.31 1.88 10.34 14.50 70.68 1.45 1.30 1.49 15.38 66.68
BreastCervix 9.81 2.80 3.51 2.17 3.42 9.57 102.54 2.79 0.78 2.67 9.14 107.33Corpus and Uterus,NOS 22.55 3.69 6.12 4.27 6.21 22.89 98.54 3.66 1.17 3.81 23.66 95.32Ovary 11.58 6.41 1.81 7.45 1.57 10.07 115.08 6.73 1.11 6.55 10.28 112.66Urinary Bladder 6.36 1.69 3.77 2.19 4.20 7.08 89.83 1.77 1.24 1.77 7.42 85.78Kidney and Renal Pelvis 14.02 2.87 4.89 2.47 4.68 13.43 104.40 2.95 0.84 2.77 12.99 107.93Brain and Other Nervous System 5.47 3.79 1.44 3.88 1.55 5.86 93.31 3.69 1.05 3.83 5.92 92.35Hodgkin's Disease 2.24 0.32 7.11 0.26 9.05 2.85 78.59 0.28 0.96 0.31 2.83 79.29Non-Hodgkin's Lymphomas 14.44 4.57 3.16 4.64 3.47 15.87 90.98 4.43 1.05 4.61 16.02 90.12Multiple Myeloma 5.30 2.44 2.17 2.43 1.89 4.62 114.71 2.28 1.06 2.47 4.68 113.24Leukemias 11.40 5.08 2.24 5.17 2.14 10.89 104.63 5.03 1.03 5.11 10.95 104.06
Sum of Rates for White Females 216.18 221.04 97.80 224.42 96.33
Sum of Rates for Whites 258.81 268.09 96.54 270.84 95.67
SSR1: 11 of 21
National Program of Cancer Registries - Cancer Surveillance System
SSR1 - Standard Status Report - 2017 November
Texas - 2014
Estimated Completeness Summary
Interim Completeness Estimates Adjusted for Reference Mortality
Whites Blacks Race Proportional
Percent Complete
Population Percent Complete
Population Percent Complete
Population
95.67 21,855,149 100.37 3,461,502 96.31 25,316,651
Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records
TotalIncedence Cases 107232
AdjustedTotal Incidence Cases 107232
Race Proportional Completeness,Adjusted for Reference Mortality 96.31
ExpectedIncidence Cases 111335
%Unresolved Duplicates* 0.00
Final Completeness Estimates,Adjusted for Reference Mortalityand Duplicate Records 96.31
* 0.00 indicates all duplicates are resolved.
SSR1: 12 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Blacks
Texas - 2013
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Males 2013 2012 - 2013 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2012 - 2013 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 12.51 5.47 2.29 4.83 2.95 16.16 77.39 5.19 0.93 5.40 15.94 78.49Esophagus 5.15 5.10 1.01 5.82 1.14 5.83 88.47 5.00 1.17 5.27 6.02 85.64Stomach 15.60 8.92 1.75 8.34 1.65 14.72 105.96 7.80 1.07 9.04 14.93 104.52Colon and Rectum 54.93 27.73 1.98 24.52 2.20 61.02 90.03 26.72 0.92 27.27 60.02 91.53Liver 22.49 15.77 1.43 11.52 1.43 22.48 100.03 14.52 0.79 15.12 21.55 104.35Pancreas 16.51 14.54 1.14 14.82 1.14 16.59 99.53 14.40 1.03 14.63 16.69 98.95Lung and Bronchus 92.63 71.48 1.30 65.28 1.27 91.14 101.63 69.09 0.94 70.70 90.14 102.76
Melanoma of the Skin
ProstateUrinary Bladder 17.24 5.09 3.39 5.34 3.66 18.61 92.66 5.08 1.05 5.14 18.80 91.69Kidney and Renal Pelvis 25.16 6.48 3.88 5.54 4.46 28.92 87.00 6.55 0.85 6.28 28.03 89.76Brain and Other Nervous System 5.12 3.25 1.57 3.19 1.50 4.90 104.65 3.09 1.03 3.28 4.93 103.97Hodgkin's Disease 2.99 0.12 24.60 0.39 7.74 0.94 317.90 0.34 1.15 0.13 0.97 308.36Non-Hodgkin's Lymphomas 17.31 4.67 3.71 5.36 3.11 14.50 119.32 4.87 1.10 4.76 14.79 116.98Multiple Myeloma 18.00 8.21 2.19 7.47 2.07 17.01 105.84 7.68 0.97 8.17 16.92 106.41Leukemias 16.58 7.76 2.14 7.40 1.81 14.04 118.11 8.29 0.89 7.60 13.74 120.69
Sum of Rates for Black Males 322.23 326.86 98.58 323.46 99.62
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Females 2013 2012 - 2013 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2012 - 2013 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 4.80 1.36 3.52 1.35 3.73 5.09 94.26 1.17 1.16 1.41 5.25 91.41Esophagus 1.43 1.15 1.25 1.77 1.27 1.46 98.27 1.51 1.17 1.19 1.51 95.01Stomach 7.36 4.54 1.62 3.92 1.91 8.69 84.74 3.79 1.03 4.57 8.75 84.15Colon and Rectum 41.70 15.62 2.67 16.09 2.48 38.78 107.53 16.65 0.97 15.51 38.52 108.26Liver 6.16 3.49 1.76 3.31 1.33 4.65 132.35 3.94 0.84 3.38 4.50 136.71Pancreas 14.11 11.54 1.22 12.17 1.20 13.79 102.28 11.76 1.04 11.62 13.89 101.56Lung and Bronchus 46.76 35.15 1.33 33.60 1.44 50.56 92.48 33.51 1.00 35.17 50.59 92.43
Melanoma of the Skin
BreastCervix 8.86 3.92 2.26 3.70 2.43 9.53 92.95 3.98 0.93 3.86 9.40 94.28Corpus and Uterus,NOS 24.43 7.49 3.26 8.31 3.10 23.22 105.20 7.65 1.09 7.62 23.63 103.41Ovary 9.80 5.13 1.91 6.32 1.44 7.38 132.73 5.63 1.12 5.25 7.56 129.59Urinary Bladder 4.76 1.88 2.53 2.42 2.68 5.04 94.55 2.10 1.15 1.94 5.19 91.79Kidney and Renal Pelvis 13.90 2.62 5.31 2.38 5.37 14.05 98.88 2.96 0.80 2.51 13.50 102.94Brain and Other Nervous System 3.63 2.19 1.66 2.13 1.63 3.57 101.63 2.39 0.89 2.14 3.49 103.85Hodgkin's Disease 2.87 0.27 10.80 0.24 9.50 2.52 113.65 0.34 0.70 0.25 2.37 120.87Non-Hodgkin's Lymphomas 11.91 3.93 3.04 3.38 3.53 13.87 85.93 3.38 1.00 3.92 13.86 85.96Multiple Myeloma 13.75 6.41 2.15 5.46 2.10 13.47 102.04 5.65 0.97 6.37 13.39 102.72Leukemias 7.84 3.48 2.25 4.47 1.96 6.81 115.06 4.51 0.99 3.47 6.80 115.31
Sum of Rates for Black Females 224.07 222.50 100.71 222.19 100.84
Sum of Rates for Blacks 271.59 273.02 99.48 271.22 100.25
SSR1: 13 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Whites
Texas - 2013
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Males 2013 2012 - 2013 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2012 - 2013 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 17.69 4.20 4.22 3.81 4.76 19.98 88.56 4.10 0.93 4.14 19.70 89.81Esophagus 7.37 6.10 1.21 7.59 1.09 6.62 111.25 6.13 1.24 6.39 6.94 106.20Stomach 8.06 4.63 1.74 3.74 2.20 10.18 79.12 4.47 0.84 4.48 9.85 81.79Colon and Rectum 44.68 17.76 2.52 16.83 2.62 46.56 95.96 17.47 0.96 17.63 46.22 96.67Liver 14.99 9.47 1.58 6.98 1.44 13.59 110.25 9.60 0.73 8.95 12.85 116.61Pancreas 13.54 11.66 1.16 12.60 1.14 13.25 102.24 11.59 1.09 11.86 13.48 100.50Lung and Bronchus 64.65 50.36 1.28 54.08 1.31 65.93 98.06 49.10 1.10 51.38 67.27 96.11Melanoma of Skin 19.08 3.89 4.91 4.47 6.87 26.70 71.48 3.75 1.19 4.04 27.72 68.86
ProstateUrinary Bladder 29.34 6.77 4.33 8.02 4.68 31.70 92.58 6.70 1.20 7.04 32.95 89.07Kidney and Renal Pelvis 24.60 6.88 3.58 5.79 3.84 26.43 93.07 6.65 0.87 6.70 25.74 95.55Brain and Other Nervous System 8.23 5.50 1.50 5.78 1.42 7.83 105.07 5.24 1.10 5.62 7.99 102.94Hodgkin's Disease 2.63 0.56 4.68 0.43 7.09 3.99 65.94 0.54 0.81 0.54 3.83 68.60Non-Hodgkin's Lymphomas 21.59 7.78 2.78 7.75 3.02 23.50 91.88 7.39 1.05 7.85 23.72 91.00Multiple Myeloma 8.06 3.87 2.09 4.00 1.86 7.21 111.83 3.73 1.07 3.92 7.31 110.21Leukemias 18.86 9.28 2.03 9.33 1.95 18.14 104.01 9.18 1.02 9.31 18.19 103.69
Sum of Rates for White Males 303.37 321.60 94.33 323.76 93.70
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Females 2013 2012 - 2013 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2012 - 2013 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 5.72 1.40 4.09 1.33 4.93 6.89 83.01 1.39 0.96 1.39 6.83 83.73Esophagus 1.46 1.16 1.26 1.47 1.19 1.38 105.91 1.17 1.26 1.22 1.45 100.75Stomach 4.48 2.54 1.76 2.00 1.99 5.05 88.59 2.49 0.80 2.44 4.85 92.21Colon and Rectum 31.04 11.46 2.71 11.88 2.82 32.33 96.02 11.20 1.06 11.60 32.72 94.85Liver 4.81 3.25 1.48 2.25 1.33 4.34 110.93 3.31 0.68 3.04 4.06 118.54Pancreas 10.10 8.76 1.15 9.37 1.15 10.09 100.04 8.78 1.07 8.87 10.23 98.71Lung and Bronchus 43.82 31.61 1.39 36.76 1.47 46.47 94.28 30.99 1.19 32.79 48.21 90.89Melanoma of Skin 10.88 1.50 7.27 1.88 10.34 15.46 70.35 1.45 1.30 1.58 16.39 66.37
BreastCervix 9.42 2.72 3.46 2.17 3.42 9.31 101.17 2.79 0.78 2.60 8.89 105.90Corpus and Uterus,NOS 21.94 3.65 6.01 4.27 6.21 22.67 96.79 3.66 1.17 3.77 23.44 93.63Ovary 11.32 6.76 1.67 7.45 1.57 10.62 106.59 6.73 1.11 6.91 10.85 104.34Urinary Bladder 6.74 1.80 3.74 2.19 4.20 7.57 88.97 1.77 1.24 1.89 7.93 84.96Kidney and Renal Pelvis 14.02 3.06 4.58 2.47 4.68 14.34 97.79 2.95 0.84 2.96 13.87 101.10Brain and Other Nervous System 5.93 3.67 1.62 3.88 1.55 5.68 104.52 3.69 1.05 3.71 5.73 103.44Hodgkin's Disease 2.08 0.32 6.41 0.26 9.05 2.94 70.86 0.28 0.96 0.32 2.91 71.49Non-Hodgkin's Lymphomas 15.43 4.68 3.30 4.64 3.47 16.24 94.98 4.43 1.05 4.72 16.40 94.09Multiple Myeloma 4.91 2.26 2.17 2.43 1.89 4.28 114.72 2.28 1.06 2.29 4.33 113.25Leukemias 11.00 5.28 2.08 5.17 2.14 11.31 97.25 5.03 1.03 5.31 11.38 96.71
Sum of Rates for White Females 215.08 226.97 94.76 230.47 93.32
Sum of Rates for Whites 259.09 274.13 94.51 276.97 93.51
SSR1: 14 of 21
National Program of Cancer Registries - Cancer Surveillance System
SSR1 - Standard Status Report - 2017 November
Texas - 2013
Estimated Completeness Summary
Interim Completeness Estimates Adjusted for Reference Mortality
Whites Blacks Race Proportional
Percent Complete
Population Percent Complete
Population Percent Complete
Population
93.51 21,537,741 100.25 3,380,525 94.43 24,918,266
Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records
TotalIncedence Cases 104939
AdjustedTotal Incidence Cases 104939
Race Proportional Completeness,Adjusted for Reference Mortality 94.43
ExpectedIncidence Cases 111133
%Unresolved Duplicates* 0.00
Final Completeness Estimates,Adjusted for Reference Mortalityand Duplicate Records 94.43
* 0.00 indicates all duplicates are resolved.
SSR1: 15 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Blacks
Texas - 2012
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Males 2012 2011 - 2012 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2011 - 2012 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 12.97 5.87 2.21 4.83 2.95 17.33 74.83 5.19 0.93 5.79 17.09 75.89Esophagus 4.25 5.39 0.79 5.82 1.14 6.15 69.03 5.00 1.17 5.56 6.36 66.83Stomach 16.09 7.47 2.15 8.34 1.65 12.34 130.36 7.80 1.07 7.58 12.51 128.59Colon and Rectum 54.29 27.89 1.95 24.52 2.20 61.39 88.44 26.72 0.92 27.44 60.38 89.92Liver 21.15 15.56 1.36 11.52 1.43 22.18 95.37 14.52 0.79 14.91 21.26 99.49Pancreas 15.83 13.99 1.13 14.82 1.14 15.96 99.19 14.40 1.03 14.07 16.05 98.62Lung and Bronchus 94.51 72.99 1.29 65.28 1.27 93.06 101.56 69.09 0.94 72.18 92.03 102.69
Melanoma of the Skin
ProstateUrinary Bladder 20.41 4.67 4.37 5.34 3.66 17.09 119.42 5.08 1.05 4.72 17.27 118.18Kidney and Renal Pelvis 26.32 6.75 3.90 5.54 4.46 30.12 87.40 6.55 0.85 6.54 29.19 90.17Brain and Other Nervous System 4.91 3.03 1.62 3.19 1.50 4.55 107.81 3.09 1.03 3.05 4.58 107.10Hodgkin's Disease 2.25 0.29 7.68 0.39 7.74 2.27 99.30 0.34 1.15 0.30 2.34 96.32Non-Hodgkin's Lymphomas 15.35 5.24 2.93 5.36 3.11 16.26 94.39 4.87 1.10 5.34 16.59 92.54Multiple Myeloma 16.47 8.26 1.99 7.47 2.07 17.12 96.20 7.68 0.97 8.22 17.02 96.72Leukemias 15.62 8.30 1.88 7.40 1.81 15.00 104.13 8.29 0.89 8.12 14.68 106.40
Sum of Rates for Black Males 320.42 330.83 96.86 327.37 97.88
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Females 2012 2011 - 2012 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2011 - 2012 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 5.33 1.15 4.64 1.35 3.73 4.28 124.37 1.17 1.16 1.18 4.42 120.62Esophagus 1.97 1.41 1.40 1.77 1.27 1.78 110.66 1.51 1.17 1.45 1.84 106.99Stomach 7.88 4.32 1.82 3.92 1.91 8.27 95.34 3.79 1.03 4.35 8.33 94.68Colon and Rectum 41.22 18.30 2.25 16.09 2.48 45.43 90.73 16.65 0.97 18.17 45.12 91.34Liver 5.09 3.67 1.39 3.31 1.33 4.88 104.36 3.94 0.84 3.55 4.72 107.79Pancreas 14.62 12.58 1.16 12.17 1.20 15.04 97.21 11.76 1.04 12.67 15.14 96.52Lung and Bronchus 54.57 37.23 1.47 33.60 1.44 53.55 101.92 33.51 1.00 37.25 53.58 101.87
Melanoma of the Skin
BreastCervix 11.63 3.95 2.94 3.70 2.43 9.62 120.89 3.98 0.93 3.90 9.49 122.62Corpus and Uterus,NOS 20.90 7.00 2.99 8.31 3.10 21.69 96.36 7.65 1.09 7.12 22.07 94.71Ovary 9.25 6.17 1.50 6.32 1.44 8.89 104.01 5.63 1.12 6.32 9.11 101.55Urinary Bladder 5.69 2.35 2.43 2.42 2.68 6.29 90.54 2.10 1.15 2.42 6.48 87.90Kidney and Renal Pelvis 16.05 3.55 4.52 2.38 5.37 19.08 84.10 2.96 0.80 3.41 18.33 87.56Brain and Other Nervous System 3.48 2.08 1.67 2.13 1.63 3.40 102.46 2.39 0.89 2.04 3.32 104.69Hodgkin's Disease 1.67 0.26 6.34 0.24 9.50 2.50 66.72 0.34 0.70 0.25 2.35 70.95Non-Hodgkin's Lymphomas 13.48 3.59 3.76 3.38 3.53 12.67 106.34 3.38 1.00 3.59 12.67 106.37Multiple Myeloma 13.68 5.76 2.37 5.46 2.10 12.11 112.91 5.65 0.97 5.72 12.03 113.65Leukemias 8.73 5.08 1.72 4.47 1.96 9.95 87.80 4.51 0.99 5.07 9.93 87.99
Sum of Rates for Black Females 235.24 239.43 98.25 238.92 98.46
Sum of Rates for Blacks 276.45 283.64 97.46 281.71 98.18
SSR1: 16 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Whites
Texas - 2012
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Males 2012 2011 - 2012 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2011 - 2012 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 16.85 3.97 4.24 3.81 4.76 18.92 89.06 4.10 0.93 3.92 18.65 90.32Esophagus 6.93 6.30 1.10 7.59 1.09 6.84 101.29 6.13 1.24 6.60 7.16 96.69Stomach 8.54 4.43 1.92 3.74 2.20 9.75 87.54 4.47 0.84 4.29 9.43 90.49Colon and Rectum 46.37 17.66 2.63 16.83 2.62 46.30 100.16 17.47 0.96 17.54 45.96 100.90Liver 14.79 9.68 1.53 6.98 1.44 13.90 106.45 9.60 0.73 9.15 13.14 112.59Pancreas 14.02 11.65 1.20 12.60 1.14 13.24 105.93 11.59 1.09 11.85 13.47 104.13Lung and Bronchus 67.23 53.30 1.26 54.08 1.31 69.79 96.33 49.10 1.10 54.39 71.20 94.41Melanoma of Skin 18.44 3.90 4.73 4.47 6.87 26.76 68.89 3.75 1.19 4.05 27.78 66.36
ProstateUrinary Bladder 28.71 6.60 4.35 8.02 4.68 30.88 92.98 6.70 1.20 6.86 32.10 89.45Kidney and Renal Pelvis 26.03 6.86 3.80 5.79 3.84 26.34 98.80 6.65 0.87 6.68 25.66 101.43Brain and Other Nervous System 8.02 5.21 1.54 5.78 1.42 7.41 108.20 5.24 1.10 5.31 7.57 106.00Hodgkin's Disease 2.95 0.57 5.13 0.43 7.09 4.07 72.36 0.54 0.81 0.55 3.92 75.27Non-Hodgkin's Lymphomas 22.54 7.65 2.95 7.75 3.02 23.11 97.56 7.39 1.05 7.72 23.33 96.64Multiple Myeloma 8.32 3.96 2.10 4.00 1.86 7.38 112.71 3.73 1.07 4.02 7.49 111.08Leukemias 18.67 9.42 1.98 9.33 1.95 18.40 101.44 9.18 1.02 9.45 18.46 101.13
Sum of Rates for White Males 308.40 323.09 95.45 325.32 94.80
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Females 2012 2011 - 2012 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2011 - 2012 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 6.03 1.41 4.27 1.33 4.93 6.96 86.69 1.39 0.96 1.40 6.90 87.44Esophagus 1.40 1.11 1.25 1.47 1.19 1.32 105.60 1.17 1.26 1.17 1.39 100.46Stomach 4.52 2.49 1.82 2.00 1.99 4.95 91.34 2.49 0.80 2.39 4.76 95.07Colon and Rectum 30.97 11.63 2.66 11.88 2.82 32.81 94.41 11.20 1.06 11.77 33.21 93.26Liver 4.65 3.37 1.38 2.25 1.33 4.49 103.54 3.31 0.68 3.15 4.20 110.65Pancreas 10.38 8.76 1.18 9.37 1.15 10.10 102.76 8.78 1.07 8.88 10.24 101.39Lung and Bronchus 45.69 32.69 1.40 36.76 1.47 48.05 95.09 30.99 1.19 33.91 49.84 91.68Melanoma of Skin 11.02 1.51 7.32 1.88 10.34 15.57 70.77 1.45 1.30 1.60 16.51 66.76
BreastCervix 9.09 2.73 3.33 2.17 3.42 9.34 97.30 2.79 0.78 2.61 8.93 101.85Corpus and Uterus,NOS 20.49 3.51 5.83 4.27 6.21 21.82 93.90 3.66 1.17 3.63 22.56 90.84Ovary 11.05 7.36 1.50 7.45 1.57 11.56 95.57 6.73 1.11 7.52 11.81 93.56Urinary Bladder 6.58 1.82 3.61 2.19 4.20 7.67 85.85 1.77 1.24 1.91 8.03 81.98Kidney and Renal Pelvis 13.66 2.93 4.67 2.47 4.68 13.71 99.62 2.95 0.84 2.83 13.26 102.99Brain and Other Nervous System 5.67 3.45 1.64 3.88 1.55 5.33 106.32 3.69 1.05 3.48 5.39 105.22Hodgkin's Disease 2.31 0.27 8.53 0.26 9.05 2.45 94.25 0.28 0.96 0.27 2.43 95.10Non-Hodgkin's Lymphomas 15.65 4.52 3.46 4.64 3.47 15.71 99.59 4.43 1.05 4.57 15.86 98.65Multiple Myeloma 5.02 2.18 2.31 2.43 1.89 4.12 121.80 2.28 1.06 2.20 4.17 120.24Leukemias 11.54 5.45 2.12 5.17 2.14 11.68 98.82 5.03 1.03 5.48 11.74 98.27
Sum of Rates for White Females 215.73 227.66 94.76 231.23 93.30
Sum of Rates for Whites 261.91 275.22 95.17 278.12 94.04
SSR1: 17 of 21
National Program of Cancer Registries - Cancer Surveillance System
SSR1 - Standard Status Report - 2017 November
Texas - 2012
Estimated Completeness Summary
Interim Completeness Estimates Adjusted for Reference Mortality
Whites Blacks Race Proportional
Percent Complete
Population Percent Complete
Population Percent Complete
Population
94.04 21,271,166 98.18 3,308,215 94.60 24,579,381
Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records
TotalIncedence Cases 103094
AdjustedTotal Incidence Cases 103094
Race Proportional Completeness,Adjusted for Reference Mortality 94.60
ExpectedIncidence Cases 108977
%Unresolved Duplicates* 0.00
Final Completeness Estimates,Adjusted for Reference Mortalityand Duplicate Records 94.60
* 0.00 indicates all duplicates are resolved.
SSR1: 18 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Blacks
Texas - 2011
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Males 2011 2010 - 2011 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2010 - 2011 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 13.98 4.92 2.84 4.83 2.95 14.51 96.34 5.19 0.93 4.85 14.31 97.70Esophagus 5.89 6.18 0.95 5.82 1.14 7.07 83.30 5.00 1.17 6.39 7.30 80.63Stomach 14.30 8.43 1.70 8.34 1.65 13.91 102.81 7.80 1.07 8.54 14.11 101.41Colon and Rectum 61.26 30.81 1.99 24.52 2.20 67.80 90.36 26.72 0.92 30.30 66.68 91.87Liver 22.54 14.44 1.56 11.52 1.43 20.59 109.51 14.52 0.79 13.85 19.74 114.23Pancreas 15.03 14.17 1.06 14.82 1.14 16.16 93.00 14.40 1.03 14.25 16.26 92.47Lung and Bronchus 93.79 78.11 1.20 65.28 1.27 99.59 94.17 69.09 0.94 77.25 98.49 95.22
Melanoma of the Skin
ProstateUrinary Bladder 16.82 5.61 3.00 5.34 3.66 20.51 82.04 5.08 1.05 5.67 20.72 81.18Kidney and Renal Pelvis 23.70 6.50 3.65 5.54 4.46 28.97 81.81 6.55 0.85 6.30 28.08 84.41Brain and Other Nervous System 5.38 2.82 1.91 3.19 1.50 4.25 126.64 3.09 1.03 2.84 4.27 125.81Hodgkin's Disease 2.68 0.58 4.66 0.39 7.74 4.45 60.25 0.34 1.15 0.59 4.59 58.44Non-Hodgkin's Lymphomas 16.29 5.44 3.00 5.36 3.11 16.89 96.44 4.87 1.10 5.55 17.23 94.55Multiple Myeloma 16.95 8.11 2.09 7.47 2.07 16.80 100.90 7.68 0.97 8.06 16.71 101.45Leukemias 14.82 8.97 1.65 7.40 1.81 16.23 91.33 8.29 0.89 8.78 15.88 93.33
Sum of Rates for Black Males 323.44 347.72 93.02 344.37 93.92
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
Black Females 2011 2010 - 2011 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2010 - 2011 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 5.18 1.17 4.43 1.35 3.73 4.36 118.77 1.17 1.16 1.20 4.50 115.18Esophagus 1.78 1.30 1.37 1.77 1.27 1.65 107.96 1.51 1.17 1.34 1.70 104.38Stomach 7.16 3.46 2.07 3.92 1.91 6.61 108.32 3.79 1.03 3.48 6.66 107.58Colon and Rectum 42.39 20.06 2.11 16.09 2.48 49.80 85.11 16.65 0.97 19.92 49.47 85.69Liver 5.07 4.14 1.22 3.31 1.33 5.51 92.04 3.94 0.84 4.01 5.33 95.07Pancreas 15.42 13.65 1.13 12.17 1.20 16.32 94.53 11.76 1.04 13.74 16.43 93.87Lung and Bronchus 49.97 36.84 1.36 33.60 1.44 52.98 94.32 33.51 1.00 36.86 53.01 94.27
Melanoma of the Skin
BreastCervix 8.94 4.90 1.82 3.70 2.43 11.93 74.96 3.98 0.93 4.83 11.76 76.03Corpus and Uterus,NOS 22.76 7.10 3.20 8.31 3.10 22.02 103.36 7.65 1.09 7.23 22.40 101.60Ovary 9.39 7.29 1.29 6.32 1.44 10.50 89.45 5.63 1.12 7.47 10.76 87.33Urinary Bladder 6.44 2.43 2.65 2.42 2.68 6.50 99.02 2.10 1.15 2.50 6.70 96.13Kidney and Renal Pelvis 15.75 3.29 4.79 2.38 5.37 17.67 89.13 2.96 0.80 3.16 16.97 92.79Brain and Other Nervous System 3.43 1.92 1.78 2.13 1.63 3.14 109.15 2.39 0.89 1.88 3.07 111.53Hodgkin's Disease 1.87 0.40 4.68 0.24 9.50 3.80 49.20 0.34 0.70 0.38 3.57 52.32Non-Hodgkin's Lymphomas 10.72 3.01 3.57 3.38 3.53 10.62 100.99 3.38 1.00 3.00 10.61 101.02Multiple Myeloma 13.25 5.50 2.41 5.46 2.10 11.57 114.53 5.65 0.97 5.47 11.50 115.29Leukemias 9.94 5.66 1.76 4.47 1.96 11.08 89.71 4.51 0.99 5.65 11.06 89.91
Sum of Rates for Black Females 229.46 246.05 93.26 245.49 93.47
Sum of Rates for Blacks 274.90 295.21 93.12 293.30 93.69
SSR1: 19 of 21
National Program of Cancer Registries - Cancer Surveillance SystemSSR1 - Standard Status Report - 2017 November
Estimated Completeness of Case Ascertainment for Whites
Texas - 2011
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Males 2011 2010 - 2011 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2010 - 2011 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 17.49 4.00 4.38 3.81 4.76 19.03 91.90 4.10 0.93 3.94 18.76 93.20Esophagus 7.37 6.33 1.16 7.59 1.09 6.87 107.28 6.13 1.24 6.63 7.19 102.40Stomach 8.65 4.43 1.95 3.74 2.20 9.75 88.75 4.47 0.84 4.29 9.43 91.74Colon and Rectum 46.44 18.12 2.56 16.83 2.62 47.51 97.75 17.47 0.96 17.99 47.16 98.47Liver 14.67 9.49 1.55 6.98 1.44 13.63 107.67 9.60 0.73 8.98 12.89 113.88Pancreas 13.20 11.80 1.12 12.60 1.14 13.41 98.45 11.59 1.09 12.01 13.64 96.77Lung and Bronchus 68.75 54.85 1.25 54.08 1.31 71.81 95.75 49.10 1.10 55.96 73.27 93.84Melanoma of Skin 23.53 4.30 5.47 4.47 6.87 29.53 79.68 3.75 1.19 4.46 30.66 76.75
ProstateUrinary Bladder 28.30 6.55 4.32 8.02 4.68 30.65 92.31 6.70 1.20 6.81 31.86 88.81Kidney and Renal Pelvis 24.81 6.58 3.77 5.79 3.84 25.28 98.13 6.65 0.87 6.41 24.63 100.74Brain and Other Nervous System 8.37 5.05 1.66 5.78 1.42 7.19 116.41 5.24 1.10 5.16 7.34 114.04Hodgkin's Disease 3.13 0.57 5.52 0.43 7.09 4.02 77.81 0.54 0.81 0.54 3.86 80.94Non-Hodgkin's Lymphomas 22.77 7.80 2.92 7.75 3.02 23.57 96.62 7.39 1.05 7.88 23.80 95.70Multiple Myeloma 7.66 4.01 1.91 4.00 1.86 7.48 102.40 3.73 1.07 4.07 7.59 100.92Leukemias 17.14 9.45 1.81 9.33 1.95 18.48 92.75 9.18 1.02 9.48 18.53 92.46
Sum of Rates for White Males 312.27 328.20 95.15 330.61 94.45
Texas NPCR and US Mortality Initial Results Mortality Adjustment Terms Adjusted for Mortality
Age-Adjusted Rates (2000 US) Age-Adjusted Rates (2000 US) Expected Initial Registry AdjReg Expected Interim
White Females 2011 2010 - 2011 Inc/Mort 2011 - 2015 Inc/Mort Incidence Percent 2011 - 2015 Adjust. 2010 - 2011 Incedence Percent
Cancer Site Incidence Mortality Ratio Mortality Ratio Rate Complete Mort Rate Term Mort Rate Rate CompleteOral Cavity and Pharynx 6.15 1.37 4.48 1.33 4.93 6.77 90.92 1.39 0.96 1.36 6.71 91.71Esophagus 1.38 1.21 1.14 1.47 1.19 1.44 95.77 1.17 1.26 1.27 1.51 91.11Stomach 4.66 2.57 1.81 2.00 1.99 5.12 90.99 2.49 0.80 2.47 4.92 94.70Colon and Rectum 31.58 11.70 2.70 11.88 2.82 33.02 95.65 11.20 1.06 11.84 33.42 94.48Liver 4.70 3.31 1.42 2.25 1.33 4.41 106.46 3.31 0.68 3.10 4.13 113.77Pancreas 10.02 8.78 1.14 9.37 1.15 10.12 99.06 8.78 1.07 8.89 10.26 97.74Lung and Bronchus 44.26 33.47 1.32 36.76 1.47 49.20 89.97 30.99 1.19 34.72 51.03 86.74Melanoma of Skin 12.66 1.60 7.93 1.88 10.34 16.52 76.67 1.45 1.30 1.69 17.51 72.33
BreastCervix 9.61 2.53 3.79 2.17 3.42 8.66 110.99 2.79 0.78 2.42 8.28 116.17Corpus and Uterus,NOS 21.49 3.33 6.45 4.27 6.21 20.67 103.95 3.66 1.17 3.44 21.37 100.56Ovary 11.62 7.60 1.53 7.45 1.57 11.93 97.42 6.73 1.11 7.76 12.19 95.36Urinary Bladder 6.54 1.77 3.71 2.19 4.20 7.42 88.19 1.77 1.24 1.85 7.77 84.21Kidney and Renal Pelvis 12.89 3.03 4.26 2.47 4.68 14.17 90.94 2.95 0.84 2.93 13.71 94.01Brain and Other Nervous System 6.05 3.44 1.76 3.88 1.55 5.33 113.52 3.69 1.05 3.48 5.38 112.35Hodgkin's Disease 1.91 0.24 7.95 0.26 9.05 2.18 87.80 0.28 0.96 0.24 2.16 88.58Non-Hodgkin's Lymphomas 15.55 4.67 3.33 4.64 3.47 16.21 95.89 4.43 1.05 4.71 16.37 94.99Multiple Myeloma 4.87 2.32 2.10 2.43 1.89 4.40 110.86 2.28 1.06 2.35 4.45 109.44Leukemias 11.10 5.51 2.01 5.17 2.14 11.81 93.99 5.03 1.03 5.54 11.87 93.47
Sum of Rates for White Females 217.05 229.37 94.63 233.03 93.14
Sum of Rates for Whites 264.50 278.61 94.93 281.65 93.80
SSR1: 20 of 21
National Program of Cancer Registries - Cancer Surveillance System
SSR1 - Standard Status Report - 2017 November
Texas - 2011
Estimated Completeness Summary
Interim Completeness Estimates Adjusted for Reference Mortality
Whites Blacks Race Proportional
Percent Complete
Population Percent Complete
Population Percent Complete
Population
93.80 20,980,669 93.69 3,233,824 93.78 24,214,493
Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records
TotalIncedence Cases 101439
AdjustedTotal Incidence Cases 101439
Race Proportional Completeness,Adjusted for Reference Mortality 93.78
ExpectedIncidence Cases 108165
%Unresolved Duplicates* 0.00
Final Completeness Estimates,Adjusted for Reference Mortalityand Duplicate Records 93.78
* 0.00 indicates all duplicates are resolved.
SSR1: 21 of 21
Submission Summary Report (SSR2)National Program of Cancer Registries
Cancer Surveillance System Data Submitted 2017 November
Diagnosis Years 2011-2016
Texas
Department of Health and Human ServicesCenters for Disease Control and Prevention
Safer . Healthier . People
SSR2: 1 of 6
Table 1: Submission Summary
* Invasive records include in situ bladder.** Includes all submitted records from the NPCR reference year through 2010.
Submission Date: Nov 30, 2017 NAACCR Record Version: 160NPCR Reference Year: 1995 Years Submitted: 1995-2015 Diagnosis Year 2016 Submission Date : Jan 31, 2018
Record Status
Diagnosis Year Records Received Non-reportable Records Reportable Records Expected Inv.
Records Invasive Records* In Situ Records Benign Brain Records
2016 93971 0 93971 113930 86753 3879 3339
2015 118533 0 118533 111617 107298 6743 4492
2014 118204 0 118204 111335 107232 6376 4596
2013 115603 0 115603 111133 104939 6285 4379
2012 113313 0 113313 108977 103094 5666 4553
2011 111518 1 111517 108165 101439 5678 4400
<= 2010 ** 1506704 9 1506695 1515460 1412106 69368 24988
Prior to NPCR Reference Year 0 0 0 0 0 0 0
Total 2177846 10 2177836 2180617 2022861 103995 50747
Texas
SSR2 - Submission Summary Report - 2017 November
National Program of Cancer Registries - Cancer Surveillance System
SSR2: 2 of 6
Texas
SSR2 - Submission Summary Report - 2017 November
National Program of Cancer Registries - Cancer Surveillance System
Table 2a: Number and Percentage Single and Inter-field Errors
The percentage of records with errors is based on NPCR Reportable Records.- Percentage not calculated.
Edit Name2016 2015 2014 2013 2012 2011
Commentn % n % n % n % n % n %
TNM Edition Number, TNM Fields (NPCR) 0 0.00 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00
Total Records with Single and Inter-field Errors 0 0.00 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00
Total Single and Inter-field Errors 0 - 1 - 0 - 0 - 0 - 0 -
Total NPCR-Reportable Records 93971 - 118533 - 118204 - 115603 - 113313 - 111517 -
SSR2: 3 of 6
Texas
SSR2 - Submission Summary Report - 2017 November
National Program of Cancer Registries - Cancer Surveillance System
Table 2b: Inter-Record Edit Errors by Error Type Among Individuals with Multiple Primaries (1995-2016)*
N/A: Not Applicable.All Inter-Record edit errors that occur within a record are listed individually.* N = 168209 represents the number of patients with two or more diagnoses of primary cancer.** Total patient count and total error count may not add up since a patient could have multiple errors. The percentage of individuals with Inter-Record errors is the number of individuals with at least one error divided by the total number of individuals with multiple primaries.
Edit Name ** Number Percentage Comment
Total Number of Inter-Record Edit Errors 0 N/A
Total Number and Percentage of Patients with Inter-record Edit Errors 0 0.00
SSR2: 4 of 6
Texas
SSR2 - Submission Summary Report - 2017 November
National Program of Cancer Registries - Cancer Surveillance System
Table 3 : Percentage of Over-Ride Flagged Fields -- Grouped by Edit Name and Diagnosis Year
The number of records used for this table are from the NPCR Reportable Records in Table 1.* To determine the percent of records with over-ride flags, multiple flags within a record are counted as one record regardless of the number of flags.** Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Research Data, Nov 2015 Sub (1973-2012) - National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
Note: Override data stopped being included in the SEER data as of the 2015 submission.
OVER-RIDE FLAG NAME
Age/Site/Morph[1990]
SeqNo/DxConf[2000]
Site/Lat/SeqNo[2010]
Site/Type[2030]
Histology
[2040]
Report Source [2050]
III-defineSite
[2060]
Leuk,Lymphoma
[2070]
Site/Behavior
[2071]
Site/Lat/Morph[2074]
ASSOCIATED EDIT NAME
DiagnosisYear
Age. PrimarySite,
Morphology(NAACCR IF15)
DiagnosticConfirm, SeqNum-Central(SEER IF23)
Site/Histology/Laterality/Sequence
Number (IR09)
Primary Site,Morphology-Type Check(SEER IF25)
1 =Morphology--
Type&Behavior(SEER MORPH)
2 = DiagnosticConfirmation,Behavior Code (SEER IF31)
3 = Both1 and 2Apply
Type of Report Srce(DC),Seq Num--Central (SEER IF04)
Seq Num--Central, Primary
Site, Morph(SEER IF22)
DiagnosticConfirmation,
Histologc Type(SEER IF48)
Primary Site,Behavior
Code(SEER IF39)
Laterality,Primary Site,Morphology(SEER IF42)
2016 0.09 1.11 0.00 0.85 0.02 0.02 0.03 0.56 0.06 0.00 0.01 0.02
2015 0.10 1.20 0.05 1.12 0.03 0.00 0.03 0.28 0.09 0.01 0.02 0.02
2014 0.09 0.99 0.05 1.28 0.02 0.01 0.02 0.03 0.09 0.00 0.02 0.02
2013 0.11 1.01 0.04 1.39 0.03 0.00 0.04 0.01 0.17 0.01 0.01 0.02
2012 0.11 1.27 0.06 1.51 0.03 0.01 0.03 0.01 0.31 0.01 0.01 0.02
2011 0.09 1.30 0.04 1.43 0.03 0.00 0.02 0.00 0.18 0.01 0.01 0.02
Percentage ofRecords with
Over- Rideflags*
2.12
2.55
2.47
2.68
3.21
2.99
SEER OVER-RIDE FLAG QUALITY MEASURES**
0.09 0.98 0.44 1.27 0.08 0.01 0.01 0.12 0.39 0.01 0.03 0.05
SSR2: 5 of 6
Texas
SSR2 - Submission Summary Report - 2017 November
National Program of Cancer Registries - Cancer Surveillance System
Table 4: Median Percentage of Over-Ride Flags for All 2017 November NPCR Data Submissions
To Calculate the Total Records with Over-Ride Flags,multiple flags within a record are counted as one record. Only 12-month data and most recent 5 years of data are displayed.
OVER-RIDE FLAG NAME
Age/Site/Morph
SeqNo/DxConf
Site/Lat/SeqNo Site/Type
HistologyReportSource
III-defineSite
Leuk,Lymphoma
Site/Behavior
Site/Lat/Morph1 = SEER
Morph2 = SEER
IF313 = Both1 and 2
Item Number
Dignosis Year Statistic [1990] [2000] [2010] [2030] [2040] [2050] [2060] [2070] [2071] [2074]
2016Median 0.07 0.63 0.08 1.03 0.02 0.00 0.00 0.00 0.27 0.00 0.01 0.00
Range 0.02-0.51 0.08-4.29 0.00-0.67 0.50-1.74 0.00-0.73 0.00-0.02 0.00-0.12 0.00-1.08 0.01-0.72 0.00-0.04 0.00-0.09 0.00-0.04
2015Median 0.06 0.82 0.11 1.02 0.02 0.00 0.01 0.02 0.33 0.00 0.01 0.01
Range 0.00-1.63 0.18-6.86 0.01-1.58 0.64-2.54 0.00-0.70 0.00-0.04 0.00-0.04 0.00-2.69 0.09-0.73 0.00-0.05 0.00-0.07 0.00-0.07
2014Median 0.07 0.88 0.14 1.06 0.02 0.00 0.01 0.03 0.36 0.00 0.01 0.00
Range 0.00-0.25 0.26-6.77 0.01-3.15 0.59-2.23 0.00-0.76 0.00-0.03 0.00-0.06 0.00-1.87 0.09-0.75 0.00-0.04 0.00-0.08 0.00-0.07
2013Median 0.07 0.86 0.11 1.02 0.02 0.00 0.01 0.03 0.38 0.00 0.01 0.01
Range 0.00-0.33 0.34-6.58 0.03-3.20 0.48-1.93 0.00-0.75 0.00-0.03 0.00-0.08 0.00-4.45 0.16-0.84 0.00-0.04 0.00-0.05 0.00-0.07
2012Median 0.08 0.81 0.12 1.12 0.02 0.00 0.01 0.04 0.39 0.00 0.01 0.00
Range 0.02-0.21 0.35-7.25 0.04-4.10 0.55-1.96 0.00-0.93 0.00-0.02 0.00-0.10 0.00-2.13 0.22-0.84 0.00-0.10 0.00-0.06 0.00-0.08
2011Median 0.08 0.78 0.12 1.16 0.02 0.00 0.00 0.03 0.39 0.00 0.01 0.00
Range 0.02-0.29 0.22-5.40 0.04-3.24 0.67-2.25 0.00-0.82 0.00-0.03 0.00-0.07 0.00-1.67 0.16-0.93 0.00-0.05 0.00-0.07 0.00-0.11
Percentage of TotalRecords with
Over-Ride Flags
2.150.79 - 6.05
2.411.65 - 8.63
2.511.63 - 8.58
2.541.51 - 8.48
2.591.44 - 9.49
2.601.70 - 7.49
SSR2: 6 of 6
Data Quality Indicator Report (DQI) National Program of Cancer Registries
Cancer Surveillance System Data Submitted 2017 November
Diagnosis Years 2011-2015
Texas
Department of Health and Human ServicesCenters for Disease Control and Prevention
Safer . Healthier . People
DQI: 1 of 5
National Program of Cancer Registries - Cancer Surveillance System
DQI - Data Quality Indicator Report - 2017 November
Texas
Table 1: Cancer Surveillance Data
2011 2012 2013 2014 2015NPCR Median
(Range)SEER Median
(Range)**
Data Quality Indicator* \ Diagnosis Year TX NPCR Median(Range) TX NPCR Median
(Range) TX NPCR Median(Range) TX NPCR Median
(Range) TX NPCR Median(Range) 2011-2015 2010-2014
Demographics
County at Diagnosis [90]
Blank 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
Unknown (999) 0.00 0.01 (0.00 - 0.77) 0.01 0.01 (0.00 - 0.73) 0.01 0.01 (0.00 - 0.44) 0.00 0.02 (0.00 - 0.88) 0.00 0.01 (0.00 - 2.76) 0.01 (0.00 - 2.76) 0.00 (0.00 - 1.05)
County Recode (000) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 (0.00 - 100) 0.00 (0.00 - 0.00)
Spanish/Hispanic Origin [190]
Blank 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 100 (100 - 100)
Unknown (9) 0.60 1.74 (0.00 - 14.55) 0.28 1.77 (0.00 - 13.44) 0.34 1.93 (0.00 - 10.87) 0.32 2.21 (0.00 - 11.74) 0.51 1.88 (0.00 - 20.58) 1.88 (0.00 - 20.58) 0.00 (0.00 - 0.00)
Birthplace Country [254]
NOS (ZZN, ZZC, ZZS, ZZP, ZZE, ZZF, ZZA, ZZX) 0.48 0.09 (0 - 3.24) 0.68 0.07 (0.00 - 3.12) 1.05 0.08 (0.00 - 2.88) 1.38 0.07 (0.00 - 2.51) 1.17 0.07 (0.00 - 2.19) 0.07 (0.00 - 3.24) N/A
Blank or Unknown (ZZU) 59.93 51.49 (8.02 - 89.15) 53.52 53.64 (9.72 - 87.36) 47.40 51.56 (9.41 - 89.41) 49.17 50.5 (10.32 - 88.02) 55.42 58.2 (11.77 - 87.04) 53.26 (8.02 - 89.41) N/A
Birthplace State [252]
(for Birthplace Country = USA only) NOS (YY) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) N/A
(for Birthplace Country = USA only) Blank or Unknown (ZZ) 0.00 0.00 (0.00 - 0.29) 0.00 0.00 (0.00 - 1.33) 0.00 0.00 (0.00 - 5.96) 0.00 0.00 (0.00 - 6.39) 0.00 0.00 (0.00 - 5.46) 0.00 (0.00 - 6.39) N/A
(for Birthplace Country = USA only) Invalid (XX) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) N/A
Tumor Characteristics
Sequence Number-Central [380]
Two or more (01 - 35) 19.15 24.29 (17.29 - 30.53) 19.34 24.19 (16.4 - 30.37) 18.92 24.02 (16.17 - 29.81) 17.26 23.47 (16.32 - 28.74) 14.60 22.26 (14.6 - 27.77) 23.78 (14.6 - 30.53) 23.79 (15.44 - 28.63)
Unspecified (99) 0.00 0.00 (0.00 - 0.01) 0.00 0.00 (0.00 - 0) 0.00 0.00 (0.00 - 0.02) 0.00 0.00 (0.00 - 0.02) 0.00 0.00 (0.00 - 0.04) 0.00 (0.00 - 0.04) 0.00 (0.00 - 0.03)
Date of Diagnosis [390]
Month (blank) 2.82 0.31 (0.00 - 2.82) 2.42 0.32 (0.00 - 5.2) 1.72 0.28 (0.00 - 3.92) 1.55 0.21 (0.00 - 3.72) 1.66 0.18 (0.00 - 2.62) 0.24 (0.00 - 5.2) 0.00 (0.00 - 0.00)
Topography [400]
Other/Ill Defined Sites (C76.0 - C76.8) 0.14 0.1 (0.02 - 0.24) 0.13 0.11 (0.02 - 0.19) 0.14 0.1 (0.02 - 0.2) 0.12 0.1 (0.00 - 0.2) 0.05 0.08 (0.02 - 0.19) 0.1 (0.00 - 0.24) 0.07 (0.00 - 2.3)
Unknown Primary Site (C80.9) 1.81 1.83 (1.1 - 2.95) 1.89 1.83 (1.15 - 2.71) 1.68 1.78 (1.14 - 3.2) 1.71 1.68 (1.23 - 3.12) 1.58 1.7 (1.1 - 2.69) 1.77 (1.1 - 3.2) 1.43 (0.76 - 2.42)
Morphology [420]
Non-specific Neoplasms (8000 - 8005) 6.56 3.44 (2.22 - 7.04) 6.66 3.48 (1.98 - 7.95) 6.24 3.49 (2.11 - 7.17) 6.23 3.55 (1.94 - 6.96) 6.76 3.6 (1.98 - 7.56) 3.48 (1.94 - 7.95) 2.63 (1.73 - 6.22)
Diagnostic Confirmation [490] excludes DCO
Not Microscopically Confirmed (5, 6, 7, 8) 4.58 3.85 (0.23 - 6) 4.74 4.17 (1.99 - 6.49) 5.01 4.22 (2.13 - 6.59) 5.42 4.39 (2.13 - 6.73) 5.65 4.09 (2.15 - 6.71) 4.17 (0.23 - 6.73) 4.68 (2.71 - 9.74)
Unknown (9) and Blank 3.92 0.79 (0.00 - 4.82) 3.44 0.95 (0.02 - 7.04) 2.94 0.82 (0.02 - 4.09) 3.01 0.76 (0.03 - 3.45) 3.15 0.58 (0.02 - 5.44) 0.75 (0.00 - 7.04) 0.66 (0.08 - 3.1)
Tumor Miscellaneous
Grade [440] (9, blank) excludes DCO, C80.9 41.95 32.03 (26.11 - 41.95) 42.64 34.55 (29.37 - 47.26) 41.89 34.55 (30.33 - 47.98) 40.29 33.51 (29.74 - 40.53) 39.40 33.18 (29.45 - 40.08) 33.52 (26.11 - 47.98) 33.46 (28.95 - 40.42)
Laterality [410] paired organs only
Only 1 side and side NOS (3) 0.23 0.1 (0.00 - 1.15) 0.21 0.1 (0.00 - 0.91) 0.20 0.11 (0.00 - 1.3) 0.23 0.1 (0.00 - 0.94) 0.28 0.08 (0.00 - 1.44) 0.1 (0.00 - 1.44) 0.09 (0.00 - 1.41)
Unknown (9, blank) 4.22 2.02 (1.07 - 5.29) 3.59 2.05 (0.83 - 4.78) 3.48 2 (1.14 - 4.65) 3.30 1.93 (0.95 - 4.49) 3.17 1.88 (0.68 - 3.9) 1.97 (0.68 - 5.29) 1.44 (0.88 - 3.31)
Summary Stage
Derived Summary Stage 2000 [3020]
Unknown/Unstaged (9) 11.63 4.45 (2.25 - 11.63) 9.93 3.89 (1.83 - 10.48) 9.16 3.68 (1.83 - 9.56) 9.01 3.47 (1.65 - 9.01) 9.22 3.22 (1.51 - 11.41) 3.68 (1.51 - 11.63) 2.65 (1.45 - 8.06)
Blank 0.00 0.00 (0.00 - 5.32) 0.00 0.00 (0.00 - 5.62) 0.00 0.00 (0.00 - 9.09) 0.01 0.00 (0.00 - 8.48) 0.00 0.00 (0.00 - 6.7) 0.00 (0.00 - 9.09) 0.00 (0.00 - 0.00)
First Course Treatment
RX Summ Surg Prim Site [1290]
DQI: 2 of 5
National Program of Cancer Registries - Cancer Surveillance System
DQI - Data Quality Indicator Report - 2017 November
Texas
Table 1: Cancer Surveillance Data
2011 2012 2013 2014 2015NPCR Median
(Range)SEER Median
(Range)**
Data Quality Indicator* \ Diagnosis Year TX NPCR Median(Range) TX NPCR Median
(Range) TX NPCR Median(Range) TX NPCR Median
(Range) TX NPCR Median(Range) 2011-2015 2010-2014
Blank 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
Surgery, NOS (90) 4.11 0.36 (0.05 - 4.11) 4.31 0.32 (0.05 - 4.31) 4.25 0.35 (0.04 - 4.25) 3.81 0.31 (0.05 - 3.81) 2.28 0.28 (0.02 - 2.29) 0.32 (0.02 - 4.31) 0.15 (0.00 - 0.72)
Unknown (99) 5.10 3.07 (0.15 - 9.66) 5.85 2.66 (0.51 - 19.36) 6.94 3.09 (0.86 - 10.42) 7.61 3.13 (0.64 - 17.26) 8.64 3.18 (0.83 - 14.48) 2.98 (0.15 - 19.36) 1.29 (0.33 - 8.87)
Blank and Unknown Combined 5.10 3.07 (0.15 - 9.66) 5.85 2.66 (0.51 - 19.36) 6.94 3.09 (0.86 - 10.42) 7.61 3.13 (0.64 - 17.26) 8.64 3.18 (0.83 - 14.48) 2.98 (0.15 - 19.36) 1.29 (0.33 - 8.87)
RX Summ Scope Reg LN Sur [1292]
Blank 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
Unknown (9) 27.54 16.85 (13.65 - 27.54) 26.42 16.99 (13.6 - 31.44) 25.55 16.47 (13.58 - 25.55) 25.12 16.06 (12.97 - 25.12) 23.07 15.73 (12.55 - 23.69) 16.36 (12.55 - 31.44) 29.52 (26.11 - 36.66)
Blank and Unknown Combined 27.54 16.85 (13.65 - 27.54) 26.42 16.99 (13.6 - 31.44) 25.55 16.47 (13.58 - 25.55) 25.12 16.06 (12.97 - 25.12) 23.07 15.73 (12.55 - 23.69) 16.36 (12.55 - 31.44) 29.52 (26.11 - 36.66)
RX Summ Surg Oth Reg/Dis [1294]
Blank 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00)
Unknown (9) 13.77 3.42 (0.33 - 13.77) 13.32 3.11 (0.68 - 22.06) 13.47 3.14 (0.9 - 13.47) 13.32 3.25 (0.86 - 13.32) 10.64 2.84 (0.91 - 13.36) 3.23 (0.33 - 22.06) 1.31 (0.41 - 15.02)
Blank and Unknown Combined 13.77 3.42 (0.33 - 13.77) 13.32 3.11 (0.68 - 22.06) 13.47 3.14 (0.9 - 13.47) 13.32 3.25 (0.86 - 13.32) 10.64 2.84 (0.91 - 13.36) 3.23 (0.33 - 22.06) 1.31 (0.41 - 15.02)
Reason for No Surgery [1340]
Blank 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0) 0.00 (0.00 - 0.00)
Unknown (9) 13.40 5.36 (0.63 - 22.25) 13.48 5.32 (0.68 - 23.41) 12.16 4.4 (1.14 - 19.89) 12.20 4.97 (1.74 - 20.11) 11.64 4.66 (1.38 - 16.42) 5.04 (0.63 - 23.41) 1.44 (0.38 - 8.47)
Blank and Unknown Combined 13.40 5.36 (0.63 - 22.25) 13.48 5.32 (0.68 - 23.41) 12.16 4.4 (1.14 - 19.89) 12.20 4.97 (1.74 - 20.11) 11.64 4.66 (1.38 - 16.42) 5.04 (0.63 - 23.41) 1.44 (0.38 - 8.47)
RX Summ Radiation [1360]
Blank 0.01 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 (0.00 - 100) 100 (100 - 100)
Unknown (9) 8.22 3.52 (0.00 - 14.62) 13.08 4.25 (0.00 - 78.94) 13.00 4.19 (0.00 - 80.12) 13.34 4.17 (0.00 - 78.55) 14.92 3.5 (0.00 - 78.55) 3.85 (0.00 - 80.12) 0.00 (0.00 - 0.00)
Blank and Unknown Combined 8.23 3.79 (0.79 - 100) 13.08 5.22 (0.65 - 100) 13.00 4.97 (0.86 - 100) 13.34 5.62 (0.98 - 100) 14.92 5.4 (1.44 - 100) 4.77 (0.65 - 100) 100 (100 - 100)
RX Summ Surg/Rad Seq [1380]
Blank 0.07 0.00 (0.00 - 1.11) 1.09 0.00 (0.00 - 1.09) 0.34 0.00 (0.00 - 1.05) 0.29 0.02 (0.00 - 2.57) 0.22 0.01 (0.00 - 2.14) 0 (0.00 - 2.57) 100 (100 - 100)
Unknown (9) 1.42 0.1 (0.00 - 1.5) 1.48 0.13 (0.00 - 2.41) 1.37 0.09 (0.00 - 2.74) 1.29 0.09 (0.00 - 1.81) 1.00 0.07 (0.00 - 1.78) 0.09 (0.00 - 2.74) 0.00 (0.00 - 0.00)
Blank and Unknown Combined 1.49 0.12 (0.00 - 1.59) 2.57 0.18 (0.00 - 2.57) 1.71 0.17 (0.00 - 3.79) 1.58 0.21 (0.00 - 4.02) 1.21 0.11 (0.00 - 3.86) 0.15 (0.00 - 4.02) 100 (100 - 100)
RX Summ Chemo [1390]
Blank 0.00 0.00 (0.00 - 0.49) 0.00 0.00 (0.00 - 0.9) 0.01 0.00 (0.00 - 1.49) 0.01 0.00 (0.00 - 0.96) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 1.49) N/A
Unknown (99) 11.80 4.96 (0.67 - 17.46) 12.46 4.95 (0.98 - 78.96) 12.28 5.85 (1.26 - 81.25) 12.43 4.3 (1.05 - 78.14) 13.59 4.58 (1.37 - 77.97) 4.92 (0.67 - 81.25) N/A
Blank and Unknown Combined 11.80 5.09 (0.67 - 17.46) 12.46 4.95 (0.98 - 78.96) 12.28 5.85 (1.26 - 81.25) 12.43 4.3 (1.05 - 78.14) 13.59 4.58 (1.37 - 77.97) 4.95 (0.67 - 81.25) N/A
RX Summ Hormone [1400]
Blank 0.53 0.00 (0.00 - 0.73) 0.00 0.00 (0.00 - 0.91) 0.00 0.00 (0.00 - 1.54) 0.01 0.00 (0.00 - 1.1) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 1.54) N/A
Unknown (99) 9.75 4.37 (0.59 - 14.67) 10.10 4.67 (0.63 - 79.07) 10.32 5.18 (0.75 - 81.75) 10.06 4.05 (0.86 - 78.51) 11.14 4.01 (1.29 - 78.18) 4.46 (0.59 - 81.75) N/A
Blank and Unknown Combined 10.28 4.49 (0.59 - 15.4) 10.10 4.67 (0.63 - 79.07) 10.32 5.18 (0.75 - 81.75) 10.06 4.05 (0.86 - 78.51) 11.14 4.01 (1.29 - 78.18) 4.49 (0.59 - 81.75) N/A
RX Summ BRM [1410]
Blank 0.54 0.00 (0.00 - 0.73) 0.00 0.00 (0.00 - 0.94) 0.00 0.00 (0.00 - 1.59) 0.00 0.00 (0.00 - 1.19) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 1.59) N/A
Unknown (99) 7.62 3.58 (0.19 - 11.99) 8.23 3.99 (0.59 - 79.06) 8.94 5.69 (0.79 - 82.04) 8.74 3.48 (0.79 - 78.26) 9.06 3.46 (0.91 - 78.15) 4 (0.19 - 82.04) N/A
Blank and Unknown Combined 8.16 3.81 (0.19 - 12.72) 8.23 3.99 (0.59 - 79.06) 8.94 5.69 (0.79 - 82.04) 8.74 3.51 (0.79 - 78.26) 9.06 3.46 (0.91 - 78.15) 4.02 (0.19 - 82.04) N/A
RX Summ Other [1420]
Blank 0.53 0.00 (0.00 - 0.53) 0.00 0.00 (0.00 - 0.89) 0.00 0.00 (0.00 - 1.59) 0.00 0.00 (0.00 - 1.21) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 1.59) N/A
Unknown (9) 5.04 3.13 (0.41 - 11.91) 7.26 2.81 (0.59 - 77.6) 7.87 3.08 (0.59 - 78.82) 7.98 3.19 (0.79 - 77.01) 8.00 2.79 (0.8 - 77.19) 2.98 (0.41 - 78.82) N/A
Blank and Unknown Combined 5.57 3.15 (0.41 - 11.91) 7.26 2.85 (0.59 - 77.6) 7.87 3.08 (0.59 - 78.82) 7.98 3.19 (0.79 - 77.01) 8.00 2.79 (0.8 - 77.19) 3.06 (0.41 - 78.82) N/A
DQI: 3 of 5
National Program of Cancer Registries - Cancer Surveillance System
DQI - Data Quality Indicator Report - 2017 November
Texas
Table 1: Cancer Surveillance Data
2011 2012 2013 2014 2015NPCR Median
(Range)SEER Median
(Range)**
Data Quality Indicator* \ Diagnosis Year TX NPCR Median(Range) TX NPCR Median
(Range) TX NPCR Median(Range) TX NPCR Median
(Range) TX NPCR Median(Range) 2011-2015 2010-2014
Rad Regional RX Modality [1570]
Blank 0.01 0.00 (0.00 - 77.27) 0.03 0.00 (0.00 - 77.84) 0.02 0.00 (0.00 - 77.36) 0.01 0.00 (0.00 - 76.68) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 77.84) N/A
Other, NOS (98) 0.83 0.19 (0.00 - 2.58) 0.77 0.21 (0.00 - 2.18) 0.81 0.17 (0.00 - 0.98) 0.86 0.14 (0.00 - 2.05) 0.63 0.17 (0.00 - 10.16) 0.18 (0.00 - 10.16) N/A
Unknown (99) 8.36 3.52 (0.48 - 41.83) 13.08 4.62 (0.65 - 78.61) 13.00 4.62 (0.8 - 79.68) 13.34 4.42 (0.86 - 77.89) 14.96 4.23 (1.41 - 78.23) 4.37 (0.48 - 79.68) N/A
Blank and Unknown Combined 8.37 3.71 (0.48 - 78.28) 13.11 4.98 (0.65 - 78.82) 13.02 4.8 (0.97 - 79.68) 13.36 4.49 (0.86 - 77.89) 14.96 4.23 (1.41 - 78.23) 4.49 (0.48 - 79.68) N/A
RX Summ Systemic/Sur Seq [1639]
Blank 0.00 0.00 (0.00 - 0.97) 0.00 0.00 (0.00 - 1.56) 0.00 0.00 (0.00 - 2.05) 0.00 0 (0.00 - 2.61) 0.00 0.01 (0.00 - 1.75) 0.00 (0.00 - 2.61) N/A
Unknown (9) 2.02 0.12 (0.00 - 2.94) 2.18 0.16 (0.00 - 37.11) 2.35 0.17 (0.00 - 37.34) 2.66 0.13 (0.00 - 36.58) 1.80 0.1 (0.00 - 35.87) 0.13 (0.00 - 37.34) N/A
Blank and Unknown Combined 2.02 0.17 (0.00 - 2.94) 2.18 0.21 (0.00 - 37.13) 2.35 0.22 (0.00 - 37.43) 2.66 0.27 (0.00 - 36.75) 1.80 0.16 (0.00 - 35.95) 0.21 (0.00 - 37.43) N/A
RX Summ Transplnt/Endocr [3250]
Blank 0.54 0.00 (0.00 - 0.54) 0.00 0.00 (0.00 - 0.93) 0.00 0.00 (0.00 - 1.71) 0.01 0.00 (0.00 - 1.26) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 1.71) N/A
Unknown (99) 11.73 3.25 (0.19 - 12.56) 13.43 3.12 (0.58 - 78.57) 13.17 3.41 (0.67 - 79.94) 12.88 3.54 (0.79 - 78.22) 10.48 3.16 (0.91 - 77.87) 3.39 (0.19 - 79.94) N/A
Blank and Unknown Combined 12.27 3.4 (0.19 - 12.57) 13.43 3.27 (0.58 - 78.57) 13.17 3.41 (0.67 - 79.94) 12.89 3.54 (0.79 - 78.22) 10.48 3.16 (0.91 - 77.87) 3.4 (0.19 - 79.94) N/A
Over-Ride Usage***
Over-Ride Age/Site/Morph [1990]
Overused 0.11 0.1 (0.00 - 0.3) 0.14 0.09 (0.03 - 0.27) 0.14 0.09 (0.00 - 0.39) 0.12 0.09 (0.00 - 0.24) 0.13 0.08 (0.00 - 2.11) 0.09 (0.00 - 2.11) N/A
Over-Ride SeqNo/DxConf [2000]
Overused 0.12 0.05 (0.00 - 4.73) 0.17 0.04 (0.00 - 6.56) 0.12 0.05 (0.00 - 6.13) 0.11 0.03 (0.00 - 6.16) 0.14 0.03 (0.00 - 6.3) 0.04 (0.00 - 6.56) N/A
Over-Ride Site/Lat/SeqNo [2010]
Overused 0.02 0.03 (0.00 - 2.85) 0.04 0.03 (0.00 - 3.46) 0.03 0.03 (0.00 - 2.7) 0.02 0.03 (0.00 - 2.66) 0.01 0.01 (0.00 - 1.31) 0.03 (0.00 - 3.46) N/A
Over-Ride Site/Type [2030]
Overused 0.75 0.35 (0.05 - 1.7) 0.71 0.4 (0.06 - 1.68) 0.61 0.18 (0.04 - 1.36) 0.52 0.17 (0.05 - 1.4) 0.39 0.12 (0.02 - 1.43) 0.21 (0.02 - 1.7) N/A
Over-Ride Histology [2040]
1 = Morphology--Type & Behavior (SEER MORPH) 0.02 0.02 (0.00 - 0.92) 0.03 0.01 (0.00 - 1.04) 0.02 0.01 (0.00 - 0.79) 0.01 0.01 (0.00 - 0.79) 0.02 0.01 (0.00 - 0.71) 0.01 (0.00 - 1.04) N/A
2 = Diagnostic Confirmation, Behavior Code (SEER IF31) 0.00 0.00 (0.00 - 0.01) 0.01 0.00 (0.00 - 0.03) 0.00 0.00 (0.00 - 0.04) 0.00 0.00 (0.00 - 0.03) 0.00 0.00 (0.00 - 0.05) 0.00 (0.00 - 0.05) N/A
3 = Both 1 and 2 Apply 0.02 0 (0.00 - 0.09) 0.03 0 (0.00 - 0.09) 0.04 0.01 (0.00 - 0.09) 0.03 0.01 (0.00 - 0.08) 0.03 0 (0.00 - 0.04) 0 (0.00 - 0.09) N/A
Over-Ride Report Source [2050]
Overused 0.00 0 (0.00 - 2) 0.01 0.00 (0.00 - 2.52) 0.01 0.00 (0.00 - 5.16) 0.04 0.00 (0.00 - 2.25) 0.09 0.00 (0.00 - 3.23) 0.00 (0.00 - 5.16) N/A
Over-Ride Ill-defined Site [2060]
Overused 0.07 0.04 (0.00 - 0.47) 0.08 0.04 (0.00 - 0.55) 0.04 0.04 (0.00 - 0.47) 0.03 0.02 (0.00 - 0.56) 0.03 0.02 (0.00 - 0.45) 0.03 (0.00 - 0.56) N/A
Over-Ride Leuk, Lymphoma [2070]
Overused 0.01 0.00 (0.00 - 0.06) 0.01 0.00 (0.00 - 0.05) 0.00 0.00 (0.00 - 0.04) 0.00 0.00 (0.00 - 0.04) 0.01 0.00 (0.00 - 0.04) 0.00 (0.00 - 0.06) N/A
Over-Ride Site/Behavior [2071]
Overused 0.01 0 (0.00 - 0.07) 0.01 0 (0.00 - 0.06) 0.01 0.00 (0.00 - 0.05) 0.01 0.00 (0.00 - 0.07) 0.02 0 (0.00 - 0.06) 0 (0.00 - 0.07) N/A
Over-Ride Site/Lat/Morph [2074]
Overused 0.01 0.00 (0.00 - 0.09) 0.02 0.00 (0.00 - 0.07) 0.01 0.00 (0.00 - 0.07) 0.01 0.00 (0.00 - 0.06) 0.02 0.00 (0.00 - 0.06) 0.00 (0.00 - 0.09) N/A
Follow-Up and Vital Status
Date of Last Contact [1750] decedents only
Year (invalid) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) N/A
Year (blank) 0.01 0.00 (0.00 - 0.01) 0.00 0.00 (0.00 - 0.05) 0.00 0.00 (0.00 - 0) 0.00 0.00 (0.00 - 0.03) 0.00 0.00 (0.00 - 0.27) 0.00 (0.00 - 0.27) N/A
Date of Last Contact Flag [1751]
DQI: 4 of 5
N/A: not applicable for the diagnosis year.* For quality review only, no NPCR standards at this time. DQI expressed as percent of all invasive cancers and in situ bladder cancers, except as noted.** Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Public-Use, Nov 2016 Sub (1973-2014) - National Cancer Institute, DCCPS,Surveillance Research Program, Cancer Statistics Branch, released April 2017, based on the November 2016 submission. Some percentages are based on recoded values. NAACCR data item numbers are notedwith square brackets "[ ]" and codes with parentheses "( )."*** An override flag is deemed as overused if the record still passes the relevant edit after removing the override flag.
National Program of Cancer Registries - Cancer Surveillance System
DQI - Data Quality Indicator Report - 2017 November
Texas
Table 1: Cancer Surveillance Data
2011 2012 2013 2014 2015NPCR Median
(Range)SEER Median
(Range)**
Data Quality Indicator* \ Diagnosis Year TX NPCR Median(Range) TX NPCR Median
(Range) TX NPCR Median(Range) TX NPCR Median
(Range) TX NPCR Median(Range) 2011-2015 2010-2014
Unknown (12) 0.01 0.00 (0.00 - 0.01) 0.00 0.00 (0.00 - 0.05) 0.00 0.00 (0.00 - 0) 0.00 0.00 (0.00 - 0.03) 0.00 0.00 (0.00 - 0.27) 0.00 (0.00 - 0.27) N/A
Substate Geography
Census Tract 2010 [135]
Not Tracked (000000) 0.00 0.00 (0.00 - 5.02) 0.00 0.00 (0.00 - 9.37) 0.00 0.00 (0.00 - 19.16) 0.00 0.00 (0.00 - 19.34) 0.00 0.00 (0.00 - 1.87) 0.00 (0.00 - 19.34) N/A
Tracked, but Not Available (999999) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 0.00 (0.00 - 100) 0.00 (0.00 - 100) N/A
Blank 100.00 0.05 (0.00 - 100) 100.00 0.11 (0.00 - 100) 100.00 0.11 (0.00 - 100) 100.00 0.19 (0.00 - 100) 100.00 0.59 (0.00 - 100) 0.12 (0.00 - 100) N/A
Invalid Codes 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) N/A
Census Tr Cert 2010 [367]
Blank 0.00 0.01 (0.00 - 100) 0.01 0.01 (0.00 - 100) 0.02 0.03 (0.00 - 100) 0.03 0.03 (0.00 - 100) 0.02 0.08 (0.00 - 100) 0.02 (0.00 - 100) N/A
Unknown (9) 0.00 0.04 (0.00 - 11.68) 0.00 0.03 (0.00 - 12.01) 0.00 0.03 (0.00 - 10.73) 0.00 0.02 (0.00 - 11.28) 0.00 0.03 (0.00 - 10.6) 0.03 (0.00 - 12.01) N/A
Follow-Up and Cause of Death
Follow-Up Source Central [1791]
Blank 0.00 0.00 (0.00 - 0.12) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.12) N/A
Unknown (99) 0.00 0.01 (0.00 - 51.11) 0.01 0.01 (0.00 - 52.03) 0.01 0.01 (0.00 - 53.91) 0.02 0.03 (0.00 - 57.68) 0.02 0.02 (0.00 - 72.65) 0.01 (0.00 - 72.65) N/A
Cause of Death [1910] decedents only
Blank 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 0.00 (0.00 - 0.00) 0.00 (0.00 - 0.00) N/A
Death Cert. Avail., But No COD (7797) 0.27 0.17 (0.00 - 100) 0.19 0.1 (0.00 - 100) 0.10 0.14 (0.00 - 100) 0.55 0.35 (0.00 - 100) 0.20 0.4 (0.00 - 100) 0.2 (0.00 - 100) N/A
Death Certificate Not Available (7777) 1.34 1.42 (0.00 - 65.7) 2.14 1.34 (0.00 - 59.48) 1.78 1.51 (0.00 - 79.49) 1.76 3.11 (0.00 - 88.98) 2.58 8.59 (0.00 - 90.14) 2.18 (0.00 - 90.14) N/A
DQI: 5 of 5